

NACC UNIFORM DATA SET

Initial Visit Packet

UDSv4.0, January 2025

Copyright© 2006, 2008, 2015, 2017, 2020, 2025 University of Washington. Created and published by the ADRC Clinical Task Force (Allan Levey, MD, PhD, Chair) and the National Alzheimer's Coordinating Center (Walter A. Kukull, PhD, Director). All rights reserved.

This publication was funded by the National Institutes of Health through the National Institute on Aging (Cooperative Agreement U24 AG072122).

Table of Contents	
Form A1: Participant Demographics	3
Form A1a: Social Determinants of Health	11
Form A2: Co-Participant Demographics	17
Form A3: Participant Family History	18
Form A4: Participant Medications	21
Form A4a: ADRD-Specific Treatments	23
Form A5-D2: Participant Health History/Clinician-assessed Medical Conditions	25
Form B1: EVALUATION FORM - Vital Signs and Anthropometrics	32
Form B3: Unified Parkinson's Disease Rating Scale (UPDRS) - Motor Exam	34
Form B4: CDR Dementia Staging Instrument plus NACC FTLD Behavior & Language Domains (CDR Plus NACC FTLD)	38
Form B5: BEHAVIORAL ASSESSMENT - Neuropsychiatric Inventory Questionnaire (NPI-Q)	40
Form B6: BEHAVIORAL ASSESSMENT - Geriatric Depression Scale (GDS)	41
Form B7: FUNCTIONAL ASSESSMENT - NACC Functional Assessment Scale (FAS)	42
Form B8: EVALUATION FORM - Neurological Examination Findings	43
Form B9: Clinician Judgment of Symptoms	46
Form C2: Neuropsychological Battery Scores	51
Form C2T: Neuropsychological Battery Scores for T-cog	55
Form D1a: Clinical Syndrome	59
Form D1b: Etiological Diagnosis and Biomarker Support	64

Revisions made to this Initial Visit Packet (IVP) since release (December 2024)

Date	Description	Form(s)	Question(s)
yyyy-mm-dd		affected	affected
2024-12-18	Fixed numbering error on A1a, subquestions of Q37.	A1a	Q37a1 - Q37a15

INITIAL VISIT PACKET

UNIFORM DATA SET (UDS) VERSION 4.0



Form A1: Participant Demographics

ADRC:	PTID:	Form date:	// Visit #:_	initials:
Language:	Administration:	Mode:	Key (remote reason):	1=Too cognitively impaired
□1 English	☐ 1 Self-administered	□ 1 In-person		2=Too physically impaired
☐2 Spanish	☐2 Staff-administered	□ 2 Remote (reason):		3=Homebound/nursing home
		□ 1 Telephone □ 2 Video		4=Refused in-person visit
		☐ 3 Mail ☐ 4 Electronic (e.g., email)		5=Other

INSTRUCTIONS: This form may be completed by intake interviewer based on ADRC scheduling records, participant interview, medical records, and proxy co-participant report (according to what is deemed to be the most reliable source of information, except as indicated for specific questions that may be based on the participants perceptions and experience which only they can provide accurate information for). This information can be collected by mail-in survey, electronic capture (web-based), phone or video interview, or during the in-person visit to accommodate and lessen participant visit burden. For additional clarification and examples, see the **UDS Coding Guidebook, Form A1.** Check only one box per question unless otherwise specified.

1. What is your month and year of birth (MM / YYYYY)?			
2. In which country or region did you spend most of your childhood? (Enter three character code from Appendix 1) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. Lebanese 3. Leba	Secti	on 1 — Demographics	
most of your childhood? (Enter three character code from Appendix 1) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3. I Hiddle Eastern or North African 3. L. Lebanese 3.2. I Iranian 3.2. I Ispyrian 3.2. I Ispyrian 3.2. I Ispyrian 3.2. I Ispyrian 3.2. I Native Hawaiian or Pacific Islander 3. I Native Hawaiian 3. I Native Hawaiian 3. I Native Hawaiian 3. I Native Hawaiian 3. I Native Ha	1.	What is your month and year of birth (MM / YYYY)?	/
3a.	2.	most of your childhood?	
Handuran Chaniard	3.	What is your race and/or ethnicity? (Check all that apply and ent 3a.	3e. 1 Middle Eastern or North African 3e1. 1 Lebanese 3e2. 1 Iranian 3e3. 1 Egyptian 3e4. 1 Syrian 3e5. 1 Iraqi 3e6. 1 Israeli 3e7. 1 Other (SPECIFY, for example, Moroccan, Yemeni, Kurdish): 3f. 1 Native Hawaiian or Pacific Islander 3f1. 1 Native Hawaiian 3f2. 1 Samoan 3f3. 1 Chamorro 3f4. 1 Tongan 3f5. 1 Fijian 3f6. 1 Marshallese 3f7. 1 Other (SPECIFY, for example, Chuukese, Palauan, Tahitian): 3g. 1 White 3g1. 1 English 3g2. 1 German 3g3. 1 Irish 3g4. 1 Italian 3g5. 1 Polish 3g6. 1 Scottish 3g7. 1 Other (SPECIFY, for example, French, Swedish, Norwegian):

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Particip	ant ID: Form 0	date: / / /	Visit #:
Secti	on 1 — Demographics		continued
will be yourse	used to help us improve health, well-being,	and quality of care. By gender id	orientation, and intersex status. This information lentity, we mean the inner sense that you have of ent from your sex assigned at birth or your sexual
4.	Which term(s) best describes your current gender identity? (Check all that apply)	4a. 1 Man 4b. 1 Woman 4c. 1 Transgender man 4d. 1 Transgender woman 4e. 1 Non-binary/gender 4f. 1 Two-Spirit (if you are 4g. 1 I use a different term 4h. 1 Don't know 4i. 1 Prefer not to answe	queer e AIAN) n (SPECIFY):
5.	What sex were you assigned at birth; on you	ur original birth certificate?	☐ 1 Male ☐ 2 Female ☐ 9 Don't know ☐ 8 Prefer not to answer
6.	Have you ever been diagnosed by a medica with an intersex condition or a "Difference of born with (or developed naturally in pubert or chromosomal patterns that do not fit star	of Sex Development (DSD)" or we ty) genitals, reproductive organs,	re you 1 Yes and/ 9 Don't know
7.	Which term(s) best describes your sexual orientation? (Check all that apply)	7a. 1 Lesbian or gay 7b. 1 Straight/heterosexu 7c. 1 Bisexual 7d. 1 Two-Spirit (if you are 7e. 1 I use a different term 7f. 1 Don't know 7g. 1 Prefer not to answe	e AIAN) n (SPECIFY):
8.	What is your primary language? (Primary language is defined as the predomin your life. Please take into consideration first la use.)		
9.	Are you left- or right-handed (for example, wwiting)?	rhich hand would normally be use	d for
10a.	How many years of education have you con	npleted? (99 = Unknown)	
10b.	What is your highest achieved level of educ	ation?	☐ 1 Less than high school ☐ 2 High school or GED ☐ 3 Some college ☐ 4 Bachelor's degree ☐ 5 Master's degree ☐ 6 Doctorate ☐ 9 Don't know

4 Separated
5 Never married (or marriage was annulled)
6 Living as married / domestic partner
9 Don't know

1 Married
2 Widowed
3 Divorced

11. What is your <u>current</u> marital status?

Secti	on 1 — Demographics		continued
12.	What is your living situation?	pouse or partner lative, friend, or roommate pouse/partner, relative, or friend related) in a private residence d living, nursing home, convent)	
13.	What is your primary type of residence?	residence (apartment, condo, house) bendent group living ne, or boarding home home, hospital, or hospice g with others, in a hotel, in a shelter, living a car, or in a park)	
14.	What are the first three digits of the ZIP code of (For example, if your ZIP code is 12345, enter 123.)	of your primary residence?	(If unknown, leave blank)
15.	Have you ever served on active duty in the U.S National Guard?	. Armed Forces, military Reserves, or	☐ 0 No (IF NO, SKIP TO QUESTION 17) ☐ 1 Yes ☐ 9 Don't know
16.	Have you ever obtained medical care or prescr (VA) facility?	☐ 0 No ☐ 1 Yes ☐ 9 Don't know	
17.	How much time in total do you spend each we physically strenuous activities that cause increfor at least 10 minutes continuously? (Include activity at work, traveling to and from parecreational activities.)	1 None 2 1 hour or less 3 2.5 hours or less 4 More than 2.5 hours 8 Prefer not to answer 9 Don't know	
Secti	on 2 — Memory		
18.	Do you feel like your memory is becoming wo	rse?	0 No 1 Yes, but this does not worry me 2 Yes, and this worries me 9 Don't know / Prefer not to answer
19.	About how often do you have trouble rememb	1 Never 2 Rarely 3 Sometimes 4 Often 5 Very often 9 Don't know / Prefer not to answer	
20.	Compared to 10 years ago, would you say that worse, the same, a little better, or much better	1 Much better 2 A little better 3 The same 4 A little worse 5 Much worse 9 Don't know / Prefer not to answer	

Form date: ____ / ___ / ___ __ __ __

For A	DRC use only:		
The r	next two questions use t	he Area Deprivation Index (ADI) lookup at https://www.neighborhoodatlas.mec Enter the participant's state and full address.	dicine.wisc.edu/mapping.
21.	ADI state-only decile:	<u>—</u> —	(If unknown, leave blank)
22.	ADI national percentile	<u></u>	(If unknown, leave blank)
23.	Participant's primary of (Enter three number code is	occupation throughout their working life from Appendix 2):	(If unknown, leave blank)
24.	ADRC enrollment type:	☐ 1 Participant is supported primarily by ADRC funding (Clinical Core, Satellite Core or project) ☐ 2 Participant is supported primarily by a non-ADRC study (e.g., R01, includit supporting FTLD Module participation)	
25.	Principal referral source	□ 1 Self □ 2 Non-professional personal contact who is not a current or previous ADR spouse/partner, relative, friend, coworker) □ 3 Current or previous ADRC participant (END FORM HERE) □ 4 ADRC clinician, staff, or investigator (END FORM HERE) □ 5 Non-ADRC healthcare professional (e.g., clinician, nurse, social worker) (END GOTHER OTHER OT	ND FORM HERE)
26.	If the referral source was self-referral or a nonprofessional contact, how did the referral source learn of the ADRC? (choose most relevant option)	Community outreach event 1 ADRC sponsored event 2 Event sponsored by an external organization (e.g., Alzheimer's Association sponsored venue, community health fair, professional conference) Other ADRC outreach 3 Newsletter (mailed or digital) 4 Study flyer/brochure (mailed or digital) 5 Center website 6 Center social media (SPECIFY): 7 Center registry (SPECIFY):	n event, institution

Other registries, websites, organizations, or media promotions

8 Website (SPECIFY):

9 Media (SPECIFY):

10 Registry (SPECIFY):

88 Other (SPECIFY):

99 Unknown

Form date: ____ / ___ / ___ __ __

Visit #:

Appendix 1: Birth Country*								
Code	Country	Code	Country	Code	Country			
AFG	Afghanistan	CHN	China	GRL	Greenland			
XQZ	Akrotiri	CXR	Christmas Island	GRD	Grenada			
ALB	Albania	CPT	Clipperton Island	GLP	Guadeloupe			
DZA	Algeria	CCK	Cocos (Keeling) Islands	GUM	Guam			
ASM	American Samoa	COL	Colombia	AX2	Guantanamo Bay Naval Base			
AND	Andorra	COM	Comoros	GTM	Guatemala			
AGO	Angola	COG	Congo (Brazzaville)	GGY	Guernsey			
AIA	Anguilla	COD	Congo (Kinshasa)	GIN	Guinea			
ATA	Antarctica	COK	Cook Islands	GNB	Guinea-Bissau			
ATG	Antigua and Barbuda	XCS	Coral Sea Islands	GUY	Guyana			
ARG	Argentina	CRI	Costa Rica	HTI	Haiti			
ARM	Armenia	CIV	Cote D'Ivoire	HMD	Heard Island and McDonald Islands			
ABW	Aruba	HRV	Croatia	HND	Honduras			
XAC	Ashmore and Cartier Islands	CUB	Cuba	HKG	Hong Kong			
AUS	Australia	CUW	Curacao	XHO	Howland Island			
AUT	Austria	CYP	Cyprus	HUN	Hungary			
AZE	Azerbaijan	CZE	Czechia	ISL	Iceland			
BHS	The Bahamas	DNK	Denmark	IND	India			
BHR	Bahrain	XXD	Dhekelia	IDN	Indonesia			
XBK	Baker Island	DGA	Diego Garcia	IRN	Iran			
BGD	Bangladesh	DJI	Djibouti	IRQ	Iraq			
BRB	Barbados	DMA	Dominica	IRL	Ireland			
XBI	Bassas da India	DOM	Dominican Republic	IMN	Isle of Man			
BLR	Belarus	ECU	Ecuador	ISR	Israel			
BEL	Belgium	EGY	Egypt	ITA	Italy			
BLZ	Belize	SLV	El Salvador	JAM	Jamaica			
BEN	Benin	GNQ	Equatorial Guinea	XJM	Jan Mayen			
BMU	Bermuda	ERI	Eritrea	JPN	Japan			
BTN	Bhutan	EST	Estonia	XJV	Jarvis Island			
BOL	Bolivia	SWZ	Eswatini	JEY	Jersey			
BES	Bonaire, Sint Eustatius, and Saba	ETH	Ethiopia	XJA	Johnston Atoll			
BIH	Bosnia and Herzegovina	XEU	Europa Island	JOR	Jordan			
BWA	Botswana	FLK	Falkland Islands (Islas Malvinas)	XJN	Juan de Nova Island			
BVT	Bouvet Island	FRO	Faroe Islands	KAZ	Kazakhstan			
BRA IOT	Brazil British Indian Ocean Territory	FJI FIN	Fiji Finland	KEN XKR	Kenya Kingman Reef			
BRN	Brunei	FRA	France	KIR	Kiribati			
BGR	Bulgaria	GUF	French Guiana	PRK	North Korea			
BFA	Burkina Faso	PYF	French Polynesia	KOR	South Korea			
MMR	Burma	ATF	French Southern and Antarctic Lands	XKS	Kosovo			
BDI	Burundi	GAB	Gabon	KWT	Kuwait			
CPV	Cabo Verde	GMB	The Gambia	KGZ	Kyrgyzstan			
KHM	Cambodia	XGZ	Gaza Strip	LAO	Laos			
CMR	Cameroon	GEO	Georgia	LVA	Latvia			
CAN	Canada	DEU	Germany	LBN	Lebanon			
CYM	Cayman Islands	GHA	Ghana	LSO	Lesotho			
CAF	Central African Republic	GIB	Gibraltar	LBR	Liberia			
TCD	Chad	XGL	Glorioso Islands	LBY	Libya			
CHL	Chile	GRC	Greece	LIE	Liechtenstein			

^{*}Codes were developed by the U.S. Government and endorsed by the Federal Geographic Data Committee. https://www.fgdc.gov/standards/news/GENC

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Lithuania		dix 1: Birth Country*				
C. Luxembourg	Code (Country		Country	Code	Country
AC Macau PHL Philippines TZA Tanzania Madagascar PCN Pitcairn Islands THA Thailand Thailand PON Madagascar PCN Pitcairn Islands TLS Timor-Leste TLS Timor-Leste TLS Timor-Leste TLS Timor-Leste TS Malaysia PRT Portugal TGO Togo Togo Togo Togo Togo Togo Togo Tog	_TU L	_ithuania	PRY	Paraguay	TWN	Taiwan
Madagascar Malawi Mali Mariba Mali Mariba Mali Mariba Mali Mariba Mali Mariba Mariba Mali Mariba Mariba Mali Mariba Mali Mariba Mali Mariba Mali Mariba Mali Mariba Mariba Mali Maliba	LUX L	_uxembourg	PER		TJK	Tajikistan
Malawi POL Poland TLS Timor-Leste Malaysia PRT Portugal TGO Togo Togo Malaysia PRT Portugal TGO Togo Togo Malaysia PRT Portugal TGO Togo Togo Maldives PRI Putro Rico TKL Tokelau TGO Tokelau TGO Tokelau Mali QAT Qatar TON Tonga TAL Tokelau TGO Tokelau TGO Tokelau TGO Trinidad and Tobaq TGO Martinique RUS Russia TUN Tunisia TUR Marshall Islands ROU Romania XTR Tromelin Island TUR Turkey Mauritania RWA Rwanda TUR Turkey Turkey TGO TIME TURKEY	MAC N	Macau	PHL	Philippines	TZA	Tanzania
Malaysia PRT Portugal TGO Togo No Maldives PRI Puerto Rico TKL Tokelau Tokelau Maldives PRI Puerto Rico TKL Tokelau Tokelau Tokelau Marshall Islands REU Reunion TTO Trinidad and Tobag TM Malta REU Reunion TTO Trinidad and Tobag TM Martinique RUS Russia TUN Tunisia TUN Tunisia TUN Mauritania RWA Rwanda TUN Turkey TUN Mauritania RWA Rwanda TUN Turkey TUN Mauritania RWA Rwanda TUN Turkey SIS Mauritius BLM Saint Barthelemy TKM Turkmenistan TM Mayotte SHN Saint Helena, Ascension, and TCA Turks and Caicos Is Tristan da Cunha Tristan da Cunha Tristan da Cunha Turkay Midway Islands MAF Saint Kitts and Nevis TUV Tuvalu Ukraine Wilking Moldova SPM Saint Pierre and Miquelon UKR Ukraine Wilkingdom Wilkingdo	MDG N	Madagascar	PCN	Pitcairn Islands	THA	Thailand
Maldives PRI Puerto Rico TKL Tokelau Mali QAT Qatar TON Tonga T Malta REU Reunion TTO Trinidad and Tobag IL Marshall Islands ROU Romania XTR Tromelin Island IL Marshall Islands ROU Romania XTR Tromelin Island IL Marshall Islands ROU Romania XTR Tromelin Island IT Mauritania RWA Rwanda TUR Turkey IT Mauritania RUM Saint Barthelemy TKM Turkmenistan IT Mayotte SHN Saint Helena, Ascension, and TTCA Turks and Caicos Is IT Mayotte SHN Saint Helena, Ascension, and TTCA Turks and Caicos Is IT Mayotte SHN Saint Helena, Ascension, and TTCA Turks and Caicos Is IT Mayotte SHN Saint Helena, Ascension, and TTCA Turks and Caicos Is IT Mayotte SHN Saint Helena, Ascension, and TTCA Turks and Caicos Is IT Mayotte SHN Saint Helena, Ascension, and TTCA Turks and Caicos Is IT Mauritania UKR Ukraine UKR Ukraine IT Mauritania UKR Ukraine UKR Uruguay	ΛWI N	Malawi	POL	Poland	TLS	Timor-Leste
Mali Malta REU Reunion TTO Tringda TRU Marka REU Reunion TTO Trindda and Tobag TIL Marshall Islands ROU Romania XTR Tromelin Island Tromelin Island RUS Russia TUN Tunisia Tun	MYS N	Malaysia	PRT	Portugal	TGO	Togo
T. Malta REU Reunion TTO Trinidad and Tobaq IL Marshall Islands ROU Romania XTR Tromelin Island Q Martinique RUS Russia TUN Turisia T. Mauritania RWA Rwanda TUR Turkey IS Mauritius BLM Saint Helena, Ascension, and Tristan da Cunha T. Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha Tristan da Cunha Tristan da Cunha Tristan da Cunha Towal Waltania Walta	NDV N	Maldives	PRI	Puerto Rico	TKL	Tokelau
IL Marshall Islands	MLI N	Mali	QAT	Qatar	TON	Tonga
Q Martinique RUS Russia TUN Tunisia T Mauritania RWA Rwanda TUR Turkey IS Mauritius BLM Saint Barthelemy TKM Turkmenistan T Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha TCA Turks and Caicos Is IV Mexico KNA Saint Kitts and Nevis TUV Turks and Caicos Is IV Midway Islands MAF Saint Martin UKR Uganda IV Midway Islands MAF Saint Martin UKR Ukraine IV Moldova SPM Saint Pierre and Miquelon ARE United Kingdom IV Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom IV Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom IV Montenegro SMR San Marino AX1 Unknown IV Montenegro SMR San Marino AX1 Unknown IV Morambique SEN Senegal VUT Vary Varyauatu IV Nauru SYC Seychelles VEN Venecute IV	MLT N	Malta	REU	Reunion	TTO	Trinidad and Tobago
TI Mauritania RWA Rwanda TUR Turkey Mauritius BLM Saint Barthelemy TKM Turkmenistan T Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha X Mexico KNA Saint Kitts and Nevis TUV Tuvalu M Federated States of Micronesia LCA Saint Lucia UGA Uganda WM Midway Islands MAF Saint Martin UKR Ukraine AM Moldova SPM Saint Pierre and Miquelon ARE United Arab Emira AM Moldova SPM Saint Vincent and the Grenadines GM Mongolia WSM Samoa USA United Kingdom IE Montenegro SMR San Marino AX1 Unknown IE Monterrat STP Sao Tome and Principe URY Uruguay RM Morocco SAU Saudi Arabia UZB Uzbekistan VXT Vanuatu VX Navassa Island SRB Serbia VXT Vanuatu VX Navassa Island SLE Sierra Leone VNM Vietnam VX Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands L Nepal SGP Singapore VGB British Virgin Islands L New Zealand SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna VX Navasca Island SVN Slovenia WLF Wallis and Futuna VX Naves Bank L New Zealand SVN Slovenia WLF Wallis and Futuna VX Naves Bank VX Wake Island VX Wake Is	ΛHL N	Marshall Islands	ROU	Romania	XTR	Tromelin Island
Same Mayotte Same	ATQ N	Martinique	RUS	Russia	TUN	Tunisia
Same Mayotte Same	ИRT N	Mauritania	RWA	Rwanda	TUR	Turkey
T Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha Tristan da Cunha Mexico Micronesia Midway Islands Midway Islands MAF Saint Kitts and Nevis Midway Islands MAF Saint Martin Moldova SPM Saint Pierre and Miquelon Monaco WCT Saint Vincent and the Grenadines Mongolia Mongolia Mondor	NUS N	Mauritius	BLM	Saint Barthelemy	TKM	· ·
M Federated States of Micronesia LCA Saint Lucia UGA Uganda W Midway Islands MAF Saint Martin UKR Ukraine NA Moldova SPM Saint Pierre and Miquelon ARE United Arab Emira ON Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom GG Mongolia WSM Samoa USA United States IE Montenegro SMR San Marino AX1 Unknown R Montserrat STP Sao Tome and Principe URY Uruguay GR Morocco SAU Saudi Arabia UZB Uzbekistan DE Mozambique SEN Senegal VUT Vanuatu M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands L Nepal SGP Sindapore VGB British Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SUR Solovania WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSP Spratly Islands M North Macedonia ESP Spain M Northern Mariana Islands XSP Spratly Islands M Palau XSV Svalbard		Mayotte		Saint Helena, Ascension, and	TCA	Turks and Caicos Islands
M Federated States of Micronesia LCA Saint Lucia UGA Uganda W Midway Islands MAF Saint Martin UKR Ukraine NA Moldova SPM Saint Pierre and Miquelon ARE United Arab Emira ON Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom GG Mongolia WSM Samoa USA United States IE Montenegro SMR San Marino AX1 Unknown R Montserrat STP Sao Tome and Principe URY Uruguay GR Morocco SAU Saudi Arabia UZB Uzbekistan DE Mozambique SEN Senegal VUT Vanuatu M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands L Nepal SGP Sindapore VGB British Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SUR Solovania WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSP Spratly Islands M North Macedonia ESP Spain M Northern Mariana Islands XSP Spratly Islands M Palau XSV Svalbard	MEX N	Mexico	KNA		TUV	Tuvalu
Midway Islands MAF Saint Martin UKR Ukraine Moldova SPM Saint Pierre and Miquelon ARE United Arab Emiral GR Monaco VCT Saint Vincent and the Grenadines GR United Kingdom USA United States United States GR Montenegro SMR San Marino AX1 Unknown R Montserrat STP Sao Tome and Principe URY Uruguay URY Vanuatu URY Uruguay URY URY Uruguay URY VANUASSA Island URY URY Uruguay URY Uruguay URY URY Uruguay URY URY Uruguay URY URY Uruguay URY Uruguay URY Uruguay URY URY Uruguay URY Uruguay URY URY Uruguay URY URY URY URY URY URY URY URY	SM F	ederated States of Micronesia		Saint Lucia		
SPM Saint Pierre and Miquelon ARE United Arab Emirar On Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom WSM Samoa USA United States United States IE Montenegro SMR San Marino AX1 Unknown RM Montserrat STP Sao Tome and Principe URY Uruguay URY Uruguay URW SAMOSAM						
Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom USA United States United States Montenegro SMR San Marino AX1 Unknown URY Uruguay URY Uruguay URY Uruguay UZB Uzbekistan UZB Uzbekistan VAT Vatican City VAT Vanuatu VAT Vanuatu VAT Vanuatu VAT Vatican City UNauru SYC Seychelles VEN Venezuela VNavassa Island SLE Sierra Leone VNM Vietnam LNepal SGP Singapore VGB British Virgin Islands LNew Caledonia SYK Slovakia XWK Wake Island UNICAN SIONE SUR SUR Somalia ESH Western Sahara ANigeria ZAF South Africa YEM Yemen JNiue SGS South Georgia and South Sandwich Islands XSP Spratly Islands XSP Sprat		•				United Arab Emirates
Mongolia WSM Samoa USA United States Montenegro SMR San Marino AX1 Unknown R Montserrat STP Sao Tome and Principe URY Uruguay URY Uruguay URY Uruguay UZB Uzbekistan UZB UZB Uzbekistan UZB VAT Vatican City UZB Uzbekistan UZB VAT Vatican City UZB Uzbekistan UZB VAT Vatican City UZB UZBEKISTA VATICAN UZBEKISTA UNITED STATE UZBEKISTA UZBE				·		United Kingdom
Montenegro SMR San Marino AX1 Unknown RR Montserrat STP Sao Tome and Principe URY Uruguay Morocco SAU Saudi Arabia UZB Uzbekistan Morocco SAU Saudi Arabia Morocco VAT Vanuatu Morocco VAT Vatican City Morocco V	MNG N	Mongolia	WSM	Samoa	USA	
R Montserrat STP Sao Tome and Principe URY Uruguay R Morocco SAU Saudi Arabia UZB Uzbekistan D Mozambique SEN Senegal VUT Vanuatu M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Island D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna SNIGaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe R Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka N Oman SDN Sudan K Palau XSV Svalbard		•		San Marino		Unknown
Mozambique SEN Senegal VUT Vanuatu Mozambique SEN Serbia VAT Vatican City Mozambique SRB Serbia VAT Vatican City Mozambique SYC Seychelles VEN Venezuela Mozambique SYC Seychelles Mozambique Mozambique Mozambique SYC Seychelles Mozambique Mozambi		-		Sao Tome and Principe		Uruguay
M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard	1AR N	Morocco	SAU	Saudi Arabia	UZB	Uzbekistan
UNauruSYCSeychellesVENVenezuelaVNavassa IslandSLESierra LeoneVNMVietnamLNepalSGPSingaporeVGBBritish Virgin IslandDNetherlandsSXMSint MaartenVIRU.S. Virgin IslandsLNew CaledoniaSVKSlovakiaXWKWake IslandLNew ZealandSVNSloveniaWLFWallis and FutunaCNicaraguaSLBSoloman IslandsXWBWest BankCNigerSOMSomaliaESHWestern SaharaANigeriaZAFSouth AfricaYEMYemenDNiueSGSSouth Georgia and South Sandwich IslandsZMBZambiaKNorfolk IslandSSDSouth SudanZWEZimbabweIDNorth MacedoniaESPSpainIPNorthern Mariana IslandsXSPSpratly IslandsIRNorwayLKASri LankaINOmanSDNSudanKPakistanSURSurinameWPalauXSVSvalbard	NOZ N	Mozambique	SEN	Senegal	VUT	Vanuatu
Nepal SCP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain D Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka N Palau XSV Svalbard	MAI	Namibia	SRB	Serbia	VAT	Vatican City
SGP Singapore VGB British Virgin Island D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna SIB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard	IRU N	Nauru	SYC	Seychelles	VEN	Venezuela
D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard	(NV N	Navassa Island	SLE	Sierra Leone	VNM	Vietnam
L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard	NPL N	Nepal	SGP	Singapore	VGB	British Virgin Islands
L New Zealand SVN Slovenia WLF Wallis and Futuna XI Nicaragua SLB Soloman Islands XWB West Bank West Bank R Niger SOM Somalia ESH Western Sahara YEM Yemen ZAF South Africa YEM Yemen JUNIUE SGS South Georgia and South Sandwich Islands ZAF ZAF South Sudan ZWE Zimbabwe ZAF South Macedonia ESP Spain ZAF Spratly Islands ZAF	NLD N	Netherlands	SXM	Sint Maarten	VIR	U.S. Virgin Islands
Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain P Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka NOman SDN Sudan C Pakistan SUR Suriname W Palau XSV Svalbard	NCL N	New Caledonia	SVK	Slovakia	XWK	Wake Island
R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard	NZL N	New Zealand	SVN	Slovenia	WLF	Wallis and Futuna
A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard	NIC N	Nicaragua	SLB	Soloman Islands	XWB	West Bank
A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard	IER 1	Niger	SOM	Somalia	ESH	Western Sahara
Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe KD North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard	IGA N	Nigeria	ZAF	South Africa	YEM	Yemen
ID North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard	IIU N	Niue	SGS	_	ZMB	Zambia
IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard	NFK N	Norfolk Island	SSD	South Sudan	ZWE	Zimbabwe
IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard		North Macedonia				
R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname V Palau XSV Svalbard		Northern Mariana Islands		-		
INOmanSDNSudanKPakistanSURSurinameVPalauXSVSvalbard		Norway				
KPakistanSURSurinameVPalauXSVSvalbard		Oman .		Sudan		
V Palau XSV Svalbard		Pakistan				
•						
N Panama CHE Switzerland		•				

IATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

 $^{{\}rm *Codes\ were\ developed\ by\ the\ U.S.\ Government\ and\ endorsed\ by\ the\ Federal\ Geographic\ Data\ Committee.} \\ {\rm \underline{https://www.fgdc.gov/standards/news/GENC}}$

	endix 2: NACC Occupa			C 1	O	<i>c</i> .	0
Code	Occupation	Code	Occupation	Code	Occupation	Code	Occupation
100	Major professionals/ Higher Executives/ Proprietors of Large Concerns	200	Lesser Professionals/ Business Managers of Medium-sized Businesses	300	Administrative Personnel/Small Business Owners/ Minor Professionals	400	Clerical and Sales Workers/Technicians/ Owners of Little Businesses
101	Actuaries	201	Accountants	301	Actors	401	Bank tellers
102	Architects	202	Advertising executives	302	Administrative assistants	402	Bill collectors
103	Bank officers	203	Authors	303	Advertising agents	403	Bookkeepers
104	Certified public accountants	204	Branch managers	304	Artists	404	Claims examiners
105	Chief executives (CEO, CFO, COO)	205	Building contractors	305	Bakers	405	Drafters
106	Clergy (professionally trained)	206	Business managers	306	Beauty shop owners	406	Driving teachers
107	Commissioned officers in the military	207	Chiropractors	307	Chefs	407	Factory supervisors
108	Dentists	208	Computer programmer	308	Chief clerks	408	Small farm owners / farmers
109	Economists	209	Computer specialists	309	Clergy (not professionally trained)	409	Flower shop workers
110	Engineers (Masters level and above)	210	Database developer	310	Court reporters	410	Human resources workers
111	Financial managers	211	Editors	311	Credit managers	411	Laboratory technicians
112	Federal government officials	212	Engineers (no advanced degree)	312	Dental hygienists	412	Newsstand operators
113	Large business owners	213	Executive managers	313	Department store managers	413	Post office clerks
114	Lawyers / judges	214	Industrial farm owners	314	Deputy sheriffs	414	Railroad conductors
115	Mathematicians	215	Furniture business owners	315	Dietitians / Nutritionists	415	Railroad train engineers
116 117	Major contractors Orthodontists	216 217	Jewelers Labor relations consultants	316 317	Dispatchers Florists	416 417	Receptionists Route managers
118	Physicians	218	Librarians	318	Funeral directors	418	Sales clerks
119	Professor / University teachers	219	Manufacturing owners	319	Insurance agents	419	Secretaries / stenographe
120	Psychologists	220	Medium business owners	320	Laboratory assistants	420	Shipping clerks
121	Research scientists	221	Musicians / composers	321	Landscape planners	421	Tailors
122	Urban and regional planners	222	Nurses	322	Noncommissioned officers in the military (at or above rank of master sergeant / C.P.O.)	422	Tax clerks
123	Veterinarians	223	Office managers	323	Morticians	423	Telephone company workers
124	VP of large business	224	Opticians	324	Newspaper / TV reporters	424	Telephone operators
		225	Personnel managers	325	Photographers	425	Timekeepers
		226	Pharmacists	326	Piano teachers	426	Toll collectors
		227	Pilots	327	Radio / TV announcers	427	Tower operators
		228	Police chief / sheriff	328	Real estate agents	428	Truck dispatchers
		229	Postmaster	329	Restaurant owners	429	Typists
		230	Production managers (TV / radio)	330	Sales representatives	430	Utility workers
		231	Public administration officials	331	Service managers	431	Warehouse clerks
		232	Public health officers	332	Small business owners	432	Window store trimmers
		233	Purchasing managers	333	Store managers		
		234	Real estate brokers	334	Surveyors		
		235	Research assistants	335	Title searchers		
		236	Sales engineers	336	Tool designers		
		237	Sales managers	337	Traffic managers		
		238 239	Social workers State / Local government	338 339	Travel agents Yard masters (railroad)		
		240	officials				
		240	Teachers (Elementary & high school)				

Codo	Occupation	Code	Occupation	Code	Occupation	Code	Occupation
500	Skilled Manual Employees	500	Skilled Manual Employees (cont.)	600	Machine Operators/ Semiskilled Employees	700	Unskilled Employees
501	Auto body repairers	538	Piano tuners	601	Apprentices (electrician / printers / etc.)	701	Amusement park workers
502	Barbers	539	Plumbers	602	Assembly line workers	702	Cafeteria workers
503	Boiler repairers	540	Police officers	603	Bartenders	703	Car cleaners
504	Bookbinders	541	Postal workers	604	Building superintendents	704	Child care workers (private household)
505	Brewers	542	Printers	605	Bus drivers	705	Construction laborers
506	Cabinet makers	543	Radio / TV maintenance	606	Cab / taxi drivers	706	Dairy workers
507	Carpenters	544	Railroad brake operators	607	Cashiers	707	Deck hands
508	Cement layers / finishers	545	Repair people	608	Child care workers (not private household)	708	Farm laborers
509	Checkers / examiners / inspectors	546	Seamstresses / seamsters	609	Cooks (short order)	709	Fishers
510	Cheese makers	547	Sheet metal workers	610	Corrections workers	710	Freight handlers
511	Construction forepeople	548	Ship smiths	611	Delivery people	711	Garbage collectors
512	Die makers	549	Shoe repairers	612	Dry cleaning pressers	712	Grave diggers
513	Electricians	550	Steelworkers	613	Elevator operators	713	Homemakers
514	Engravers	551	Tile layers	614	Enlisted military personnel (other than noncommissioned officers)	714	House cleaners
515	Exterminators	552	Tool makers	615	Factory machine operators	715	Janitors
516	Firefighters	553	Upholsterers	616	Factory workers	716	Junk / recycle sorters
517	Gardeners / landscapers	554	Utility line workers	617	Foundry workers	717	Laundry workers
518	Glassblowers	555	Weavers	618	Garage and gas station assistants	718	Messengers
519	Glaziers	556	Welders	619	Greenhouse workers	719	Peddlers
520	Gun smiths			620	Guards / security watch people	720	Porters
521	Hair stylists			621	Machine operators	721	Roofing laborers
522	Heavy equipment operators			622	Meat cutters / packers	722	Shoe shiners
523	Home repairs			623	Meter readers	723	Stagehands
524	Iron workers			624	Nursing aides / attendants	724	Stock handlers
525	Kitchen workers / cooks			625	Oil delivery people	725	Street cleaners
526	Locksmiths			626	Practical nurses	726	Unemployed
527	Machinists			627	Pump operators	727	Unskilled factory workers
528	Mail carriers			628	Receivers / checkers	728	Unspecified laborers
529	Maintenance forepeople			629	Servers (waiters / waitresses)	729	Window cleaners
530	Masons			630	Signal operators (railroad)	730	Woodchoppers
531	Mechanics			631	Truck drivers	731	Worked while incarcerated
532	Millwrights			632	Wood workers		
533	Noncommissioned officers in the military (below rank of master sergeant / C.P.O.)			633	Wrappers (stores / factories)		
534	Painters						
535	Paperhangers						
536	Patrolmen						
537	Piano builders						



Form A1a: Social Determinants of Health

ADRC:	PTID:		Form date:	_//	_ Visit #: _	Examiner's initials:				
	Administration: nglish panish □ 2 Staff-administered	Mode: □ 1 In-person □ 2 Remote (reason): □ 1 Telephone □ 2 Video □ 3 Mail □ 4 Electr □ 0 Not completed (reason): _	onic (e.g., email)			1=Too cognitively impaired 2=Too physically impaired 3=Homebound/nursing home 4=Refused in-person visit 5=Other 93=Concerns about reliability				
may feel ι	INSTRUCTIONS: The following questions are designed to gather information on your current and past life experience that we think may be important for brain health. There are no right or wrong answers, and you do not have to answer any question that makes you feel uncomfortable. If the question does not apply to your experience, feel free to check Prefer not to answer . You should fill out this form on your own, without help from your co-participant or study partner.									
Sec	tion 1 — Transportatior	1								
acco	is section we are trying to und mplishing important activitie ications (these are only exam	s, such as going to the doc								
1.	Do you or someone in your h	ousehold currently own a c	ar?		0 No 1 Yes 8 Prefe	er not to answer				
2.	Do you have consistent access	s to transportation?			0 No 1 Yes 8 Prefe	er not to answer				
	et to the places they need to cations are trying to assess whe				ar, or get	a ride. The next three				
3.	In the past 30 days, how often because of a problem with tra		e the house when	you wanted to	1 Ofte 2 Som 3 Neve	etimes				
4.	In the past 30 days, how ofter get somewhere because of a			ould be able to	1 Ofte 2 Som 3 Neve	etimes				
5.	In the past 30 days, how often appointments or from doing			nedical	1 Ofte 2 Som 3 Neve	etimes				
Section 2 — Financial security										
These next set of questions are designed to assess your current and past financial situation. If you do not feel comfortable with any question in this section, you can respond Prefer not to answer .										
6.	Which of these income group Include income from all source benefits, help from relatives, This information will be kept confic- other person, organization or gove	tes such as wages, salaries, sent from property, and so following and will not be shared in	social security or r forth.	etirement	2 \$15, 3 \$30, 4 \$75, 8 Prefe	\$14,999 000 – \$29,999 ,000 – \$74,999 000 and over er not to answer 't know				
7.	How satisfied are you with yo	ur current personal financia	al condition?		1 Com 2 Satis 3 Som 4 Not	pletely satisfied				

naccmail@uw.edu NATIONAL ALZHEIMER'S COORDINATING CENTER naccdata.org

Participant ID:	Form date:	/ /	Visit #:

Sec	tion 2 — Financial security	continued
8.	How difficult is it for you to meet monthly payments on your bills?	1 Not at all 2 Slightly 3 Moderately 4 Very 5 Extremely 8 Prefer not to answer
9.	months or longer, how upsetting has it been to you? 2 Yes, financial problems upsetting to me 3 Yes, financial problems somewhat upsetting t	for twelve months or longer for twelve months or longer, but not for twelve months or longer, and o me for twelve months or longer, and
10.	At any time, did you ever eat less than you felt you should because there wasn't enough money to buy food?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
11.	<u>In the last 12 months</u> , did you ever eat less than you felt you should because there wasn't enough money to buy food?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
12.	At any time, have you ended up taking less medication than was prescribed for you because of the cost?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
13.	<u>In the last 12 months</u> , have you ended up taking less medication than was prescribed for you because of the cost?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
14.	This is a picture of a ladder with 10 steps. Each step represents a level of status as far as money, education, and jobs. The highest step is step 10. This represents people with the most money, the most education, and the best jobs. Step 1 is the lowest step. This step represents people with the least money, least education, and the worst jobs or no job. Steps in between (2 through 9) represent those people who fall somewhere between those who are best off and those who are worst off. Where would you place yourself on this ladder compared to others in your community (or neighborhood)? The closer you are to step 10 the better off you think you are. Please mark the number where you would place yourself.	Best off → 10 3 4 Worst off
15.	What was your mother's (or primary person who raised you up until age 18) highest level of education completed at the time they were raising you? 1 Never attended school 2 Grades 1 through 8 (electric time they were raising you? 3 Grades 9 through 11 (some 4 Grade 12 or GED (high 5 College 1 year to 3 year 6 College 4 years or more 8 Prefer not to answer/N 9 Do not know	ome high school) school graduate) rs (some college) e (college graduate)

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Sec	tion 3 — Social connections, activities, and environment				
	These next set of questions are designed to learn what you think about your social connections, the types of activities you spend your time on, and how you view your home and neighborhood.				
	wing are some statements to learn how you describe yourself in general. For each statemen ely represents your opinion.	t, select the number that most			
16.	I experience a general sense of emptiness	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer			
17.	I miss having people around	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer			
18.	I feel like I don't have enough friends	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer			
19.	I often feel abandoned	1 Strongly disagree 2 Disagree 3 Neither disagree or agree 4 Agree 5 Strongly agree 8 Prefer not to answer			
20.	I miss having a really close friend	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer			
The r	next four questions are about how you spend your time.				
21.	If your parents are still alive, how often do you have contact with them (including mother, father, mother-in-law, and father-in-law) either in person, by phone, mail, or email (e.g., any online interaction)?	o Parents not living 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer			
22.	If you have children, how often do you have contact with your children (including child[ren]-in-law and stepchild[ren]) either in person, by phone, mail, or email (e.g., any online interaction)?	0 Do not have children 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer			

Participant ID: _____ Form date: ___ / ___ / ___ Visit #: ____

Sec	tion	3 — Social connections, activities, and envi	ronment	continued
23.		often do you have contact with close friends either in p il (e.g., any online interaction)?	erson, by phone, mail, or	0 Do not have close friends 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer
24.	educ	often do you participate in activities outside the home cational activities, volunteer work, paid work, or activitie nizations)?	-	□ 0 Do not participate in activities outside the home □ 1 Once a year or less □ 2 Several times a year □ 3 Several times a month □ 4 Several times a week □ 5 Everyday or almost everyday □ 8 Prefer not to answer
This	next s	et of questions is about how safe you feel in different co	ntexts.	
25.	How	safe do you feel in your home and community (or neigh	nborhood)?	
	25a.	Home		1 Very safe 2 Mostly safe 3 Unsafe at times 4 Very unsafe 8 Prefer not to answer
	25b.	Community (or neighborhood)		☐ 1 Very safe ☐ 2 Mostly safe ☐ 3 Unsafe at times ☐ 4 Very unsafe ☐ 8 Prefer not to answer
Sec	tion	4 — Experiences with the healthcare syster	n	
		t five questions are about your experiences with the hea nk about your regular medical doctors (not the doctors y		
26.		e past year, how often did you delay seeking medical ntion for a problem that was bothering you?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of 5 Not applicable 8 Prefer not to answer	f the time
27.		e past year, how often did you experience challenges ling a prescription?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of 5 Not applicable 8 Prefer not to answer	f the time
28.		e past year, how often did you miss a follow-up ical appointment that was scheduled?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of 5 Not applicable 8 Prefer not to answer	f the time

Form date: ____ / ___ / ___ __ Visit #:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Sec	tion 4 — Experiences with the healthcare syster	n continued
29.	In the past year, how often did you follow a doctor's advice or treatment plan when it was given?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of the time 5 Not applicable 8 Prefer not to answer
30.	Overall, which of these describes your health insurance, access to healthcare services, and access to medications?	1 Not available to any extent 2 Below the level of my needs 3 Able to meet my needs 4 Exceeds my needs 8 Prefer not to answer
Sec	tion 5 — Experiences of Discrimination	
	arch has shown that experiences of unfair treatment in daily li wing questions about whether you have experienced unfair tr	fe, for any reason, can negatively affect health. Please answer the reatment in the following ways.
31.	In your day-to-day life how often are you treated with less courtesy or respect than other people?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
32.	In your day-to-day life how often do you receive poorer service than other people at restaurants or stores?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
33.	In your day-to-day life how often do people act as if they think you are not smart?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
34.	In your day-to-day life how often do people act as if they are afraid of you?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
35.	In your day-to-day life how often are you threatened or harassed?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer

_____ Form date: ____ / ____ / ____ __ Visit #: ___

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Partio	cipant ID: Form date:	/ / Visit #:	_
Sec	tion 5 — Experiences of Discrimination	continued	l
36.	How frequently do you receive poorer service or treatment from doctors or in hospitals compared to other people?	☐ 1 All of the time ☐ 2 Most of the time ☐ 3 Sometimes ☐ 4 None or almost none of the time ☐ 5 Not applicable ☐ 8 Prefer not to answer	
37.	When reflecting on the day-to-day experiences in questions 31 to 36, what do you think are the main reasons for these experiences? (Check all that apply)	37a1.	

37a15. □ 1 Prefer not to answer

1 Very stressful
2 Moderately stressful
3 Not stressful

9 Don't know 8 Prefer not to answer

38. When you have had day-to-day experiences like those in

questions 31 to 36, would you say they have been very stressful, moderately stressful, or not stressful?



For	m A	2: Co-participant De	mographi	CS		Forming and	
ADRC:		PTID:	F	orm date:/	'/	Examiner's Visit #: initials:	
Language: □ 1 English □ 2 Spanish		□1 In-person		on): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other		Key (not completed reason): 92=No co-participant 95=Physical problem 96=Cognitive/behavioral problem 97=Other 98=Verbal refusal	
direc		ONS: This form is to be completed by ne co-participant. For additional clari stion.					
Sec	tion 1	— Co-participant's Relatio	nship to Partio	ipant			
1.		is the co-participant's relationship ipant?	to the	fiancé(e), l 2 Child (by 3 Sibling (b 4 Other rel 5 Friend, n friends, v	boyfriend, girlfriend, blood or through m by blood or through lative (by blood or t eighbor, or some work, or commur	arriage or adoption) marriage or adoption) hrough marriage or adoption) one known through family,	er,
2.		ong has the co-participant known to participant has known the participant		_		Years (999 = Unknown)	
3.	Does	the co-participant live with the par	ticipant?	□o No		1 Yes (SKIP TO QUESTION 5	5)
4.	What is the primary mode of contact with the participant?		1 In-person 2 Telephor 3 Video co	ne	4 Texting or email 5 Social media platforms 6 Other (SPECIFY):		
4		hat is the approximate frequency o ntact?	f all types of	1 Daily 2 At least t week 3 Weekly	hree times per	4 At least three times per month 5 Monthly 6 Less than once a month	
48	W	hat is the average amount of time so th the participant during each encou	ounter?	email and	n 5 minutes ate for texting or I may be applicable nodes of contact	2 5-15 minutes 3 15-30 minutes 4 30-60 minutes 5 Longer than one hour	
5.	Is the	re a question about the co-participa	ant's reliability?	□o No		□1 Yes	
Sec	tion 2	— Co-participant's Judgme	ent of Pa <u>rticip</u>	ant's M <u>emo</u>	ry		
		three questions directly to the co-p					
6.	Do yo worse	u feel like the participant's memory ?	is becoming		this does not wor this worries me n	ry me	
7.		: how often does the participant ha nbering things?	ve trouble	1 Never 2 Rarely 3 Sometim	nes	☐ 4 Often ☐ 5 Very Often ☐ 9 Unknown	
8.	partic	ared to 10 years ago, would you say ipant's memory is much worse, a lit a little better, or much better?		1 Much be 2 A little b 3 The same	etter	4 A little worse 5 Much worse 9 Unknown	

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org



Form A3: Participant Family History

ADRC: PTID: Form date:/ / Visit #: initia	iner's Is:
Language: Mode: Key (remote reason): 1=Too cognitively impaired	
□ 1 English □ 1 In-person 2=Too physically impaired	
☐ 2 Spanish ☐ 2 Remote (reason): 3=Homebound or nursing home	
☐ 1 Telephone ☐ 2 Video 4=Refused in-person visit	
5=Other	

INSTRUCTIONS: This form is to be completed by a clinician with experience in evaluating participants with neurological and psychiatric diagnoses. Estimates are allowed if exact birth year or age at death is unknown. For additional clarification and examples, see the UDS Coding Guidebook for Form A3.

Section 1 - Biological parents

For any parent with a neurological or psychiatric diagnosis, the entire row must be filled out.

If the clinician cannot determine the primary neurological/psychiatric diagnosis after reviewing all available evidence, enter 99 = **Unknown** in the **Primary diagnosis** column, and *skip the subsequent questions in the row*. For a parent with no neurological or psychiatric diagnosis, enter **00** = **No known neurological/psychiatric diagnosis** in the **Primary diagnosis** column, and then *skip* the subsequent questions in the row. For a parent with a primary diagnosis but no secondary diagnosis, enter 88 = No secondary diagnosis in the Secondary diagnosis column.

	Birth year (9999=Unknown)	Age at death (888=N/A,	Primary dx*	Secondary dx*	Method of evaluation**	Age of onset of primary dx
		999 = Unknown)	SE	E LIST OF CODES	•••••	(999 = Unknown)
1a. Mother					_	
1b. Father					_	

Codes

*DIAGNOSES

- 00 No known neurological/psychiatric diagnosis
- 01 Alzheimer's Disease
- **02** Lewy Body dementia (includes DLB and PDD)
- 03 Vascular dementia
- 04 Stroke
- 05 FTLD* without motor neuron disease
- 06 FTLD* with motor neuron disease
- 07 Motor Neuron Disease
- 08 Parkinson's Disease
- 09 Prion pathology
- 10 Psychiatric condition
- 11 Dementia of unknown etiology
- 12 Other
- 88 No secondary diagnosis
- 99 Specific diagnosis unknown (acceptable if method of evaluation is not by exam or autopsy)

**METHOD OF EVALUATION

- 1 Participant/family report
- 2 Medical records
- (co-enrolled family members)
- 4 Autopsy (if autopsy report available)

*FTLD includes: bvFTD or FTD, PPA (any subtype), CBS or CBD, PSP

Abbreviations: bvFTD = behavioral variant frontotemporal dementia, CBS = corticobasal syndrome, CBD = corticobasal degeneration, DLB = dementia with Lewy bodies, FTD = frontotemporal dementia, PDD = Parkinson's disease with dementia, PPA = primary progressive aphasia, PSP = progressive supranuclear

ALZHEIMER'S COORDINATING naccmail@uw.edu naccdata.org

Participant ID:	Form date:	/	Visit #:
•			

YEAR OF BIRTH FOR FULL SIBLINGS & BIOLOGICAL CHILDREN: If birth year is unknown, please provide an approximate year on **UDS Initial Visit Form A3** and **UDS Follow-up Visit Form A3** so that the sibling or child with unknown birth year ends up in correct birth order relative to the other siblings/children.

Example: A participant is the oldest of three children. The participant was born in 1940 and the middle sibling in 1943; the youngest sibling's birth year is unknown. An approximate birth year of 1944 or later should be assigned to the youngest sibling.

Use that same birth year on **FTLD Module Form A3a**, *if applicable*, and across all UDS visits so that any new information on a particular sibling or child can be linked to previously submitted information. If it is impossible for the participant and co-participant to estimate the birth year, *enter* **9999=Unknown**.

Section 2 – Full siblings

2.	How many full siblings does the participant have?
	(77 = participant adopted or siblings unknown)
	If participant has no full siblings, SKIP TO QUESTION 3 ; otherwise, provide information on all full siblings.

For any full sibling with a neurological or psychiatric diagnosis, the entire row must be filled out.

If the clinician cannot determine the primary neurological/psychiatric diagnosis after reviewing all available evidence, enter **99** = **Unknown** in the **Primary diagnosis** column, and *skip the subsequent questions in the row*. For a full sibling with no neurological or psychiatric diagnosis, enter **00** = **No known neurological/psychiatric diagnosis** in the **Primary diagnosis** column, and then *skip the subsequent questions in the row*. For a full sibling with a primary diagnosis but no secondary diagnosis, enter **88** = **No secondary diagnosis** in the Secondary diagnosis column.

	Birth year (9999=Unknown)	Age at death (888=N/A,	Primary dx*	Secondary dx*	Method of evaluation**	Age of onset of primary dx
		999 = Unknown)	SE	E LIST OF CODES	•••••	(999=Unknown)
2a. Sibling 1					_	
2b. Sibling 2					_	
2c. Sibling 3					_	
2d. Sibling 4					_	
2e. Sibling 5					_	
2f. Sibling 6					_	
2g. Sibling 7					_	
2h. Sibling 8					_	
2i. Sibling 9					_	
2j. Sibling 10					_	
2k. Sibling 11					_	
2l. Sibling 12					_	
2m. Sibling 13					_	
2n. Sibling 14					_	
2o. Sibling 15					_	
2p. Sibling 16					_	
2q. Sibling 17					_	
2r. Sibling 18					_	
2s. Sibling 19					_	
2t. Sibling 20					_	

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Participant ID:	Form date:	/	Visit #:

Section 3 - Biological children

3. How many biological children does the participant have?

If participant has no biological children, **END FORM HERE**; otherwise, provide information on all biological children.

For any biological child with a neurological or psychiatric diagnosis, the entire row <u>must be filled out</u>.

If the clinician cannot determine the primary neurological/psychiatric diagnosis after reviewing all available evidence, enter **99** = **Unknown** in the **Primary diagnosis** column, and *skip the subsequent questions in the row*. For a biological child with no neurological or psychiatric diagnosis, enter **00** = **No known neurological/psychiatric diagnosis** in the **Primary diagnosis** column, and then *skip the subsequent questions in the row*. For a biological child with a primary diagnosis but no secondary diagnosis, enter **88** = **No secondary diagnosis** in the Secondary diagnosis column.

	Birth year (9999=Unknown)	Age at death (888=N/A,	Primary dx*	Secondary dx*	Method of evaluation**	Age of onset of primary dx
		999 = Unknown)	SE	E LIST OF CODES	•••••	(999 = Unknown)
3a. Child 1					_	
3b. Child 2					_	
3c. Child 3					_	
3d. Child 4					_	
3e. Child 5					_	
3f. Child 6					_	
3g. Child 7					_	
3h. Child 8					_	
3i. Child 9					_	
3j. Child 10					_	
3k. Child 11					_	
3l. Child 12					_	
3m. Child 13					_	
3n. Child 14					_	
3o. Child 15					_	



Form A4: Participant Medications

ADRC:	PTID:	Form date://	Visit #:	initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired	7	
□1 English	□ 1 In-person	2=Too physically impaired		
☐2 Spanish	☐2 Remote (reason):	3=Homebound or nursing home		
	□1 Telephone □2 Video	4=Refused in-person visit		
		5=Other		

INSTRUCTIONS: This form is to be completed by the clinician or ADRC staff. The purpose of this form is to record all prescription medications taken by the participant within the two weeks before the current visit. If the participant is receiving any treatments known to significantly impact Alzheimer's disease (AD) or Alzheimer's disease related dementias (ADRD) biomarkers as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4a ADRD-Specific Treatments form.

For prescription medications not listed here, please follow the instructions at the end of this form. OTC (non-prescription) medications need not be reported; however, a short list of medications that could be either prescription or OTC follows the prescription list. For additional clarification and examples, see **UDS Coding Guidebook** for Form A4.

Is the participant currently taking any medications? \square_0 No (END FORM HERE) \square_1 Yes

ME	DICATION NAME	RXNorm
	acetaminophen-HYDROcodone (Hycet, Vicodin)	214182
	albuterol (Proventil, ProAir HFA, RespiClick, Ventolin)	435
	alendronate (Binosto, Fosamax)	46041
	allopurinol (Aloprim, Duzallo, Zyloprim)	519
	alprazolam (Xanax)	596
	amlodipine (Norvasc)	17767
	apixaban (Eliquis)	1364430
	atenolol (Tenormin)	1202
	atorvastatin (Lipitor)	83367
	benazepril (Lotensin)	18867
	bupropion (Aplenzin, Budeprion, Wellbutrin, Zyban)	42347
	calcium acetate (Calphron, Eliphos, PhosLo Phoslyra)	214342
	carbidopa-levodopa (Duopa, Rytary, Sinemet)	103990
	carvedilol (Coreg)	20352
	celecoxib (Celebrex)	140587
	cetirizine (Aller-Tec, Zyrtec)	20610
	citalopram (Celexa)	2556
	clonazepam (Klonopin)	2598
	clopidogrel (Plavix)	32968
	cyanocobalamin (Nascobal, Vitamin B12)	11248
	diclofenac (Flector, Cambia, Zipsor)	3355
	diltiazem (Cardizem, Cardia XT, DILT-XR, Tiazac)	3443
	donepezil (Adlarity, Aricept)	135447
	duloxetine (Cymbalta, Irenka)	72625

ΛE	DICATION NAME	RXNorm
	enalapril (Vasotec)	3827
	ergocalciferol (Calcidol, Calciferol, Disdol, Vitamin D2)	4018
	escitalopram (Lexapro)	321988
	esomeprazole (Nexium)	283742
	estradiol (Estrace, Estrogel, Delestrogen, Yuvafem)	4083
	ezetimibe (Zetia)	341248
	ferrous sulfate (Feosol, Iron Supplement, Slow FE)	24947
	fexofenadine (Allegra, Wal-Flex)	87636
	finasteride (Propecia, Proscar)	25025
	fluoxetine (Prozac, Sarafem)	4493
	fluticasone (Flovent)	41126
	fluticasone nasal (Aller-Flo, Flonase)	1165656
	fluticasone-salmeterol (Advair, AirDuo)	284635
	furosemide (Lasix)	4603
	gabapentin (Gralise, Horizant, Neurontin)	25480
	galantamine (Razadyne, Reminyl)	4637
	glipizide (Glucotrol)	4821
	hydrochlorothiazide (Esidrix, Hydrodiuril, Microzide)	5487
	hydrochlorothiazide-triamterene (Dyazide, Maxzide)	548337
	latanoprost (Xalatan)	43611
	levothyroxine (Levoxyl, Synthroid, Tirosint)	10582
	lisinopril (Prinivil, Qbrelis, Zestril)	29046
	lorazepam (Ativan)	6470
	losartan (Cozaar)	52175
	lovastatin (Altocor, Altoprev, Mevacor)	6472

Part	icipant ID: Form dat	te:	/	/ Visit #:	
ME	DICATION NAME	RXNorm	ME	DICATION NAME	RXNorm
	meloxicam (Mobic, Vivlodex)	41493		potassium chloride (K-Dur 10, K-Tab, Klor-con)	8591
	memantine (Namenda)	6719		pravastatin (Pravachol)	42463
	metformin (Glucophage, Glumetza, Riomet)	6809		quetiapine (Seroquel)	51272
	metoprolol (Lopressor, Toprol-XL)	6918		ranitidine (Wal-Zan, Zantac)	9143
	mirtazapine (Remeron)	15996		rivastigmine (Exelon)	183379
	montelukast (Singulair)	88249		rosuvastatin (Crestor, Ezallor)	301542
H	naproxen (Aleve, Anaprox, Naprosyn)	7258		sertraline (Zoloft)	36437
	niacin (Niacinol, Niacor, Niaspan, Nicotinic			sildenafil (Viagra, Revatio)	136411
Ш	Acid)	7393		simvastatin (FloLipid, Zocor)	36567
	nifedipine (Adalat, Afeditab CR, Procardia)	7417		tamsulosin (Flomax)	77492
	nitroglycerin (Nitro-Bid, Nitro-Dur, Nitro-Time, Nitrostat, Rectiv)	4917		terazosin (Hytrin)	37798
	omega-3 polyunsaturated fatty acids	4301		tramadol (ConZip, Ryzolt, Ultram)	10689
	(Omacor, Lovaza, Vascazen)			trazodone (Desyrel, Oleptro)	10737
H	omeprazole (Prilosec, Zegerid)	7646		valsartan (Diovan)	69749
	oxybutynin (Ditropan, Oxytrol, Urotrol)	32675		venlafaxine (Effexor)	39786
H	pantoprazole (Protonix)	40790		warfarin (Coumadin, Jantoven)	11289
	paroxetine (Paxil, Paxil CR, Pexeva)	32937		zolpidem (Ambien, Edluar, Intermezzo, Zolpimist)	39993
	(but	that may also	o be pr	y be purchased over the counter rescription):	
ME	(but	that may also	_	·	RXNorm
ME			_	rescription):	RXNorm 82003
ME	DICATION NAME acetaminophen (Actamin, Feverall, Ofirmev,	RXNorm	_	DICATION NAME docusate (Colace, Dioctyl SS, Ducsate Calcium,	
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin)	RXNorm 161	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride,	82003
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin	161 1151	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin)	82003 4511 4845
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H)	161 1151 1191	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride,	82003 4511
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro)	161 1151 1191 1588	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist)	82003 4511 4845 5640
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H)	RXNorm 161 1151 1191 1588 214342 1897	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin)	82003 4511 4845 5640 28889
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D)	RXNorm 161 1151 1191 1588 214342	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release)	82003 4511 4845 5640 28889 6711
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D)	RXNorm 161 1151 1191 1588 214342 1897	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax)	82003 4511 4845 5640 28889 6711 221147
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D) cholecalciferol (Decara, Replesta, Vitamin D3)	161 1151 1191 1588 214342 1897 608343	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax) turmeric (Curcumin, Turmeric Root) ubidecarenone (Co Q-10) vitamin E (Alpha E, Aquasol-E, Aquavite-E,	82003 4511 4845 5640 28889 6711 221147 1114883 21406
	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D)	161 1151 1191 1588 214342 1897 608343 1008264	_	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax) turmeric (Curcumin, Turmeric Root) ubidecarenone (Co Q-10)	82003 4511 4845 5640 28889 6711 221147 1114883 21406
	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D) cholecalciferol (Decara, Replesta, Vitamin D3) chondroitin-glucosamine (Cidaflex, Osteo Bi-Flex)	161 1151 1191 1588 214342 1897 608343 1008264 2418 1008567	ME	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax) turmeric (Curcumin, Turmeric Root) ubidecarenone (Co Q-10) vitamin E (Alpha E, Aquasol-E, Aquavite-E, Centrum Singles) isted above: y using the RXNav: https://lhncbc.nlm.nih.gov/RxN	82003 4511 4845 5640 28889 6711 221147 1114883 21406 11256

Form date: ___/__/____ Visit #: ___



Examiner's

Form A4a: ADRD-Specific Treatments

ADRC: _____ PTID: _____

Language □1 Engli □2 Span	ish	i	son te (<i>reason):</i> Telephone □2 Video	Key (remote r	eason): 1=Too cognitively i 2=Too physically in 3=Homebound or i 4=Refused in-perso	npaired nursing home				
					5=Other					
dementic clinical control those the of these treatme lifetime Informa pipeline clarification.	INSTRUCTIONS: This form should be used to record treatments expected to significantly impact Alzheimer disease and related dementias (ADRD) biomarkers, whether a disease-modifying treatment that is FDA-approved for ADRD and received as part of clinical care or an investigational treatment received as part of a clinical trial. For treatments received as part of clinical care, only those that are FDA-approved for disease-modification of ADRD should be included on this form. If the participant is receiving one of these treatments as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4 Medication form. Participation in any ADRD drug trial over an individual's lifetime should be included. If available, the ClinicalTrials.gov identifier should be entered into the "specific treatment and/or trial" cell. Information on the type of treatment can be found via ClinicalTrials.gov and is summarized in "Alzheimer's disease drug development pipeline." 1 This form should be completed by the clinician based on participant interview and/or co-participant report. For additional clarification and examples, see UDS Coding Guidebook for Form A4a. Check only one box per question, unless otherwise stated. 1. Has the participant ever been prescribed a treatment or been enrolled in a clinical trial of a long of the process of the participant interview and long of the participant exercited to modify ADRD biomarkers?									
								nown (END FORM HERE)		
2.			information about the exposed to more than two		nt(s) and/or trial(s) Sals, use extended table on F	Page 2):				
		r ug Target hat apply)	Specific treatment and/ or trial	Start date (99/9999 =Unknown)	End date (month/year) (99/9999=Unknown; 88/8888=Ongoing)	How wa treatm provid	ent	If clinical trial, in which group was the participant?		
	amm aptiourop	nation c plasticity, rotection	NCT	/	/	1 Clinical 2 Clinical 3 Clinical and clin	trial care	1 Active treatment 2 Placebo 9 Unknown		
1 Tau 1 Infla 1 Syn	amm aptiourop	l beta nation c plasticity, rotection arget(s)	NCT	/	/	1 Clinical 2 Clinical 3 Clinical and clin	trial care	☐ 1 Active treatment ☐ 2 Placebo ☐ 9 Unknown		
((ARIA	A-E), amylo	d related imaging abr	normalities – hemor	naging abnormalities–e rhage (ARIA-H), or othe modify ADRD biomarke	r major	1 Yes	END FORM HERE) nown (END FORM HERE)		
	3a.	associated		ected al they 3a2. 1 A	Amyloid related imaging onormalities–edema (A Amyloid related imaging onormalities–hemorrha	RIA-E)	3a3. □ 1	Other issues		

Participant ID:	Form date:	/	/	Visit #:	

	2. Please provide information about the clinical treatment(s) and/or trial(s) (continued from Page 1):								
Primary Drug Target (check all that apply)	Specific treatment and/ or trial	Start date (month/year) (99/9999 =Unknown)	End date (month/year) (99/9999=Unknown; 88/8888=Ongoing)	How was the treatment provided?	If clinical trial, in which group was the participant?				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				

IATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

¹ Cummings et al., "Alzheimer's disease drug development pipeline: 2024," Alzheimer's and Dementia. 2024 April 24; 10(2):e12465.



Form A5-D2: Participant Health History / Clinician-assessed Medical Conditions

ADRC:	PTID:	Fo	orm date:/	_/		Examiner's nitials:
Language □1 Engli □2 Span	sh 🔲 1 In-person	Key (remote reaso	on): 1=Too cognitive 2=Too physically 3=Homebound 4=Refused in-pe 5=Other	y impaired or nursing home		
and co- included	CTIONS : This form is to be completed participant, as well as review of any mad it the form. For additional clarification, unless otherwise stated.	edical records that ar	e available. Any co	onditions ident	ified during the visi	t should be
Sectio	n 1 – Cigarette smoking, alco	ohol, and substar	nce use			
Cigare	ette smoking					
1a.	Has the participant smoked <u>more th</u> in their life — (IF NO OR UNKNOWN,S			□o No	□1 Yes	□9 UNK
1b.	Total years smoked (99 = Unknown)				_	
1c.	Average number of packs smoked po	2 1/2	cigarette to less th pack to less than pack to less than 1	1 pack	\square 4 1½ packs to le \square 5 2 packs or mo \square 9 Unknown	
1d.	Has the participant smoked within <u>t</u>	he last 30 days?		□o No	□1 Yes	□9 UNK
1e.	If the participant quit smoking, spec (i.e., quit) (888 = N/A, 999 = unknown)	ify the age at which tl	hey last smoked			
Alcoho	ol use					
1f.	In the past 12 months, how often ha had a drink containing alcohol? (IF NEVER OR UNKNOWN, SKIP TO QU		☐ 0 Never ☐ 1 Monthly or ☐ 2 2-4 times a	less	☐3 2-3 times a wo ☐4 4 or more tim ☐9 Unknown	
1g.	On a day when the participant drink beverages, how many standard drin participant typically consume? (Stan regular beer, 5oz of wine, 1.5oz of disti	ks does the Indard drink: 120z of	1 1 or 2 2 3 to 4 3 5 to 6		☐ 4 7 to 9 ☐ 5 10 or more ☐ 9 Unknown	
1h.	In the past 12 months, how often did have six or more drinks containing a		☐ 0 Never ☐ 1 Less than or ☐ 2 Monthly		□3 Weekly □4 Daily or almos □9 Unknown	t daily
Substa	ance use					
1i.	Has the participant used substances or more of the following areas: work			drugs that cau	sed significant imp	airment in one
1	1i1. Within the past 12 months			□o No	□1 Yes	□9 UNK
1	1i2. Prior to 12 months ago			□o No	□1 Yes	□9 UNK
1j.	In the past 12 months, how often ha consumed cannabis (edibles, smoked		☐ 0 Never ☐ 1 Monthly or		3 2-3 times a we	

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

Participant ID:	F	orm date:	/	/	Visit #:	

In the following sections (pages 2-7) record the presence or absence of a <u>history of these conditions</u>, as determined by the clinician's best judgment following the medical history interview with the participant and co-participant, as well as review of any medical records that are available.

	Absent:	Recent/Active:	Remote	/Inactive:	Unknow	n (UNK)
t has never been present. It happened within the last year or still requires active management.		It existed or occurred in the past (more than one year ago) but was resolved or there is no treatment currently under way.		There is insufficient information available to assesthis condition.		
Sectio	on 2 – Cardiovascu	ılar disease				
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
2a.		tery blockage) — DWN, SKIP TO QUESTION 2b)	□о	□ 1	_2	<u> </u>
2	2a1. More than one h	eart attack?		□o No	□1 Yes	☐9 UNK
2	2a2. Age at most rece	nt heart attack (999 = Unknown)				
2b.	Cardiac arrest (heart s	stopped) — DWN, SKIP TO QUESTION 2c)	□о	□ 1	_2	<u></u> 9
2	b1. Age at most rece	nt cardiac arrest (999 = Unknown)				
2c.	Atrial fibrillation		О	□1	2	<u></u> 9
2d.	Coronary artery angionstenting	oplasty / endarterectomy /	О	□ 1	2	<u></u> 9
2e.	Coronary artery bypa	ss procedure — DWN, SKIP TO QUESTION 2f)	□о	□ 1	2	<u></u> 9
2	!e1. Age at most rece	nt surgery (999 = Unknown)				
2f.		fibrillator implantation — DWN, SKIP TO QUESTION 2g)	О	□ 1	_2	<u></u> 9
:	2f1. Age at first impla	ntation (999 = Unknown)				
2g.	Congestive heart failu	ure (including pulmonary edema)	О	□1	\square_2	<u></u> 9
2h.	Heart valve replacem	ent or repair — DWN, SKIP TO QUESTION 2i)	О	□ 1	□ ₂	<u></u> 9
2	h1. Age at most rece	nt procedure (999 = Unknown)				
2i.	Other cardiovascular	disease (SPECIFY):	□о	□ 1	2	<u></u> 9
Sectio	on 3 – Cerebrovas	cular disease				
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
3a.		exam (imaging is not required) — DWN, SKIP TO QUESTION 3b)	О	<u> </u>	_2	<u> </u>
3	Ba1. More than one st	roke?		□o No	□1 Yes	☐9 UNK
3	Ba2. Age at most rece	nt stroke (999 = Unknown)				
			NEVER IMPROVED	PARTIALLY IMPROVED	IMPROVED / BACK TO NORMAL	UNKNOWN
-	Ba3. What is the statu	s of stroke symptoms?		1	\square_2	

Section	3 – Cerebrovascular disease				continued
3a4	4. Carotid artery surgery or stenting? (IF NO OR UNKNOWN, SKIP TO QUESTION 3b)		□o No	□1 Yes	□9 UNK
3a5	 Age at most recent carotid artery surgery or stenting (999 = Unknown) 				
		ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
	ransient ischemic attack (TIA) — IF ABSENT OR UNKNOWN, SKIP TO QUESTION 4a)	□о	□ 1	\square_2	□ 9
3b1	1. Age at most recent TIA (999 = Unknown)				
Section	4 - Neurologic conditions				
		ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
	Parkinson's disease (PD) — IF ABSENT OR UNKNOWN, SKIP TO QUESTION 4b)	О	□1		□ 9
4a1	1. Age at estimated PD symptom onset (999 = Unknow	n)			
	Other parkinsonism disorder (e.g., DLB) — IF ABSENT OR UNKNOWN, SKIP TO QUESTION 4c)	□0	□ 1		<u></u> 9
4b 1	1. Age at parkinsonism disorder diagnosis (999 = Unkn	own)			
f.	Epilepsy and/or history of seizures (excluding childhood ebrile seizures) — IF REMOTE/INACTIVE, SKIP TO QUESTION 4c2, IF ABSENT OR UNKNOWN, SKIP TO QUESTION 4d)	□0	□ 1	2	<u> </u>
4 c1	1. How many seizures has the participant had in the past 12 months?	□ 0 None □ 1 1 or 2 □ 2 3 or more □ 9 Unknown			
4c2	 Age at first seizure (excluding childhood febrile seizu (999 = Unknown) 	res)			
4d. C	Chronic headaches	\Box_0	□1	\square_2	□ 9
4e. N	Multiple sclerosis	\square_0	□1	\square_2	<u> </u>
4f. N	Normal – pressure hydrocephalus	□ ₀	□1	\square_2	<u></u> 9
v	Repetitive head impacts (e.g. from contact sports, intima violence, or military duty), regardless of whether it cause IF NO OR UNKNOWN, SKIP TO QUESTION 4h)	•	□o No	□1 Yes	□9 UNK
4 g1	4g1. Indicate the source(s) of exposure for repeated hits to the head: (Check all that apply) 4g1a. □ 1 American football 4g1b. □ 1 Soccer 4g1d. □ 1 Boxing or mixed martial arts 4g1e. □ 1 Other contact sport 4g1f. □ 1 Intimate partner violence 4g1g. □ 1 Military service 4g1h. □ 1 Physical assault 4g1i. □ 1 Other (SPECIFY):				
4 g2	Indicate the total length of time in years that the par exposed to repeated hits to the head (e.g. playing American football for 7 years) (999 = Unk				

Form date: ____ / ___ / ___ __ Visit #:

Section	on 4	- Neurologic conditions					continued
4h.	pla res det	ad injury (e.g. in a vehicle accident, being hit by a ying sports or biking, in an assault, or during mili ulted in a period of feeling "dazed or confused, rails of the injury, or loss of consciousness (if musider most severe episode). (IF NO OR UNKNOWN	tary serv " being ultiple he	vice) that unable to recall ead injuries,	□o No	□1 Yes	□9 UNK
4	lh1.	After a head injury, what was the longest period of time that the participant was unconscious? O Less than 5 minutes 1 5 minutes to less than 30 minutes unconscious? 3 1 day to less than 7 days 4 7 days or more 8 Not applicable, no loss of consciousness 9 Unknown duration					, no loss of
4	lh2.	After a head injury, what was the longest period that the participant was "dazed or confused" or unable to recall details of the injury?	1 5 r 2 30	ss than 5 minutes minutes to less tha minutes to less th day to less than 7 c	an 24 hours	4 7 days or more 8 Not applicable and confused 9 Unknown dura	, never dazed
4	lh3.	Total number of head injuries in which the participant felt "dazed or confused", unable to recall details of the injury or experienced loss of consciousness?	0 No	2	[3 6-12 4 13 or more 9 Unknown	
4	₽h4.	Age of <u>first</u> head injury that resulted in a period unable to recall details of the injury, or loss of					
4	lh5.	Age of most recent head injury that resulted i being unable to recall details of the injury, or					
Section	on 5	- Medical conditions					
If any o	f the	conditions still require active management and	d/or me	dications, please	select "Recent	/ Active."	
				ABSENT	RECENT/ACTIV	REMOTE/ E INACTIVE	UNKNOWN
5a.		betes —					
		ABSENT OR UNKNOWN, SKIP TO QUESTION 5b) Which type?				L 2	□9
•	oa i.	which type:			petes insipidus, lo onal diabetes, pr	atent autoimmune e ediabetes)	diabetes/type
!	5a2.	Treated with (Check all that apply)	5a2a. 5a2b. 5a2c. 5a2d. 5a2e. 5a2f.	2b. 1 Oral medications 2c. 1 GLP-1 receptor activators 2d. 1 Other non-insulin, non-GLP-1 receptor activator injection medication 2e. 1 Diet			
	5a3.	Age at diabetes diagnosis (999 = Unknown)					
5b.		oertension (or taking medication for hypertension ABSENT OR UNKNOWN, SKIP TO QUESTION 5c)	on) —	О	□ 1	\square_2	<u>9</u>
	b1.	Age at hypertension diagnosis (999 = Unknow	vn)				
5с.	cho	oercholesterolemia (or taking medication for hig elesterol) — ABSENT OR UNKNOWN, SKIP TO QUESTION 5d)	gh	□o	□ 1		<u></u> 9
	5c1.	Age at hypercholesterolemia diagnosis (999 =	= Unkno	wn)			
5d.	B12	2 deficiency		□ ₀	□ 1	2	9
5e.	Thy	roid disease		□ o	□ 1	_2	<u></u> 9

Form date: ____ / ___ / ____ ___ __

Participant ID:	Form date:	/	Visit #:

Section	on 5	- Medical conditions						continued
				AB	SENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
5f.		hritis — ABSENT OR UNKNOWN, SKIP TO QUESTION 5g)			□o	□ 1	\square_2	9
	5f1.	Type of arthritis (Check all that apply)	5f1a. 5f1b. 5f1c. 5f1d.	□1 O	heumatoi steoarthr ther (SPE nknown	itis		
	5f2.	Regions affected (Check all that apply)	5f2a. 5f2b. 5f2c. 5f2d.	□1 L0	pper extro ower extro pine nknown	•		
5g.	Inc	ontinence — urinary (occurring at least weekly,)		0	1	\square_2	<u></u> 9
5h.	Inc	ontinence — bowel (occurring at least weekly)			0	_1	\square_2	<u></u> 9
5i.		ep apnea — (IF ABSENT, REMOTE/INACTIVE, OF KNOWN, SKIP TO QUESTION 5j)	R		□ 0	□ 1	\square_2	<u> </u>
	5i1.	Typical use of breathing machine (e.g. CPAP) night over the past 12 months	at	<u></u> 2 >	one 4 hours p 4 hours p nknown			
	5i2.	Typical use of an oral device or implanted breathing pacemaker for sleep apnea at nighthe past 12 months?	nt over	2 >	one 4 hours p 4 hours p nknown			
5j.	RE	M sleep behavior disorder (RBD)			0	_1	\square_2	<u></u> 9
5k.		posomnia/Insomnia (occurring at least weekly ouiring medication)	or] 0	□ 1	□ ₂	9
5l.	Otl	ner sleep disorder (SPECIFY):			0	<u> </u>	\square_2	<u></u> 9
5m.	(Re	ncer, primary or metastatic — port all known diagnoses. Exclude non-melanon ncer. IF ABSENT OR UNKNOWN, SKIP TO QUESTIO			0	□ 1	<u>2</u>	<u></u> 9
5	m1.	Type of cancer (Check all that apply)	5m1a. 5m1b. 5m1c.	□1 M 5	letastatic m1b1.	on-metastatic (CHECK ALL THAT 1 Metastatic to I 1 Metastatic to 9	•	rain
5	m2.	Primary site of cancer: (Check all that apply)	5m2a. 5m2b. 5m2c. 5m2d. 5m2e. 5m2f.	☐1 C	lood reast olon ung rostate ther (SPE	:CIFY):		
5	m3.	Type of cancer treatment (Check all that apply)	5m3a. 5m3b. 5m3c. 5m3d. 5m3e. 5m3f. 5m3g.	☐1 S ☐1 Ir ☐1 B ☐1 C ☐1 H	adiation urgical Re nmunoth one marro hemothe ormone t tther (SPE	erapy ow transplant rapy herapy		
5	m4.	Age at most recent cancer diagnosis (999 = L	Jnknown)				

Participa	ant ID	: Form date:	//_	v	isit #:	
Section	on 5	– Medical conditions				continued
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
5n.		VID-19 infection — ABSENT OR UNKNOWN, SKIP TO QUESTION 50)	□0	□ ₁	\square_2	<u> </u>
5	in1.	Requiring hospitalization?		□o No	□1 Yes	□9 UNK
5o.	Ast	hma/COPD/pulmonary disease	По	□ 1	\square_2	<u></u> 9
5p.		ronic kidney disease — ABSENT OR UNKNOWN, SKIP TO QUESTION 5q)	□ ₀	□ 1	\square_2	<u></u> 9
5	ър1.	Age at diagnosis (999 = Unknown)				
5q.		er disease — ABSENT OR UNKNOWN, SKIP TO QUESTION 5r)	О	□1	<u>2</u>	<u> </u>
5	iq1.	Age at diagnosis (999 = Unknown)				
5r.		ipheral vascular disease — ABSENT OR UNKNOWN, SKIP TO QUESTION 5s)	□o	□ 1	\square_2	<u> </u>
!	5r1.	Age at diagnosis (999 = Unknown)				
5s.		man Immunodeficiency Virus (HIV) — ABSENT OR UNKNOWN, SKIP TO QUESTION 5t)	□0	□1	\square_2	<u></u> 9
!	5s1.	Age at diagnosis (999 = Unknown)				
5t.		ner medical conditions or procedures ECIFY):	О	□ 1	\square_2	<u> </u>
Section	on 6	- Psychiatric conditions				
		liagnose a disorder, DSM-5-TR criteria require that sy	mptoms cause cl	linically significan	t distress or impa	irment in social,
occupa	tiona	ll, or other important areas of functioning. For more gu	uidance see the U	JDS Coding Guide		D2.
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
6a.	De	pressive disorder				
6	5a1.	Major depressive disorder (DSM-5-TR criteria*)	□0	□1	□ 2	<u></u> 9
6	5a2.	Other specified depressive disorder (DSM-5-TR criteria*)	□ ₀		_2	9
•	5a3.	If Recent/Active depressive disorder (Q6a1 or Q6a2), choose if treated or untreated.	0 Untreated 1 Treated wi	th medication and	d/or counseling	
6b.	Bip	olar disorder (DSM-5-TR criteria*)	О	□ ₁	2	9
6с.		izophrenia or other psychosis disorder (DSM-5-TR eria*)	О	□ 1	\square_2	9
6d.		kiety disorder (DSM-5-TR criteria*) ABSENT OR UNKNOWN, SKIP TO QUESTION 6e)	□0	□ 1	\square_2	<u> </u>
6	id1.	Generalized Anxiety Disorder	□0	□ ₁	\square_2	<u></u> 9
6	id2.	Panic Disorder	□0	□ ₁	\square_2	<u></u> 9
6	id3.	Obsessive-compulsive disorder (OCD)	□0	□ ₁	\square_2	<u></u> 9
6	id4.	Other (SPECIFY):	□0	□ 1	\square_2	<u></u> 9
6e.		t-traumatic stress disorder (PTSD) (DSM-5-TR eria*)	О	□ 1	2	9

Participa	nt IC): 	Form date:	_ / / _	Vi	isit #:	
Section	n 6	- Psychiatric conditi	ons				continued
				ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
6f.	spe	velopmental neuropsychiat ectrum disorder [ASD], attent order [ADHD], dyslexia)		<i>n</i> □0		□ 2	<u> </u>
6g.		her psychiatric disorders PECIFY):		□о	□ 1	\square_2	<u></u> 9
Section	n 7	– Menstrual and rep	roductive health				
If questi	ons (about menstrual and reprod	uctive health are relevan	t to this participant, c	ontinue to questior	n 7a. Otherwise, E	ND FORM HERE.
7a.	(88	w old was the participant w = Never had a menstrual per NEVER HAD A MENSTRUAL I	riod, 99 = Unknown)	menstrual period?			
7b.	7b. How old was the participant when they had their last menstrual period? (88 = Still menstruating, 99 = Unknown) (IF STILL MENSTRUATING, SKIP TO QUESTION 7d)						
7с.	Tc1. 1 Natural menopause menstrual periods, please indicate the reason. (Check all that apply) 7c2. 1 Hysterectomy (surgical removal of uterus) 7c3. 1 Surgical removal of both ovaries 7c4. 1 Chemotherapy for cancer or another condition 7c5. 1 Radiation treatment or other damage/injury to reprod 7c6. 1 Hormonal supplements (e.g. the Pill, injections, Mirena 7c7. 1 Anti-estrogen medication such as Tamoxifen, anostroz exemestane (Aromasin), or letrozole (Femara) 7c8. 1 Unsure 7c9. 1 Other (SPECIFY):			ndition njury to reprodu ections, Mirena, xifen, anostrozo	HRT)		
7d.	(e.g	s the participant taken fem g. estrogen)? NO OR UNKNOWN, SKIP TO	·	nt pills or patches	□o No	□1 Yes	□9 UNK
7	d1.	How many years in total?	(99 = Unknown)				
7	d2.	Age at first use	(99 = Unknown)				
7	d3.	Age at last use	(88= Still presently usin	ng, 99 = Unknown)			
7e.		s the participant ever taken NO OR UNKNOWN, END FOR	•		□o No	□1 Yes	□9 UNK
7	'e1.	How many years in total?	(99 = Unknown)				
7	'e2.	Age at first use	(99 = Unknown)				
7	'e3.	Age at last use	(88= Still presently usin	ng, 99 = Unknown)			




Form B1: EVALUATION FORM – Vital Signs and Anthropometrics

ADRC:	PTID:	Form date: _	/ Visit #:	initials:
Language: ☐1 English ☐2 Spanish	Mode: ☐ 1 In-person ☐ 0 Not completed (reason):	Key (not completed reason):	94=Remote visit 95=Physical problem 96=Cognitive/behavioral problem 97=Other 98=Verbal refusal	

INSTRUCTIONS: This form is to be completed by the clinician or appropriately trained research personnel. For additional clarification and examples, see the **UDS Coding Guidebook** for Form B1.

Sec	Section 1 – Participant vital signs and anthropometrics						
1.	Participant height (inches)		(88.8 = not assessed)				
2.	Participant weight (lbs.)		(888 = not assessed)				

Instructions for measuring waist and hip circumference in adults



Waist circumference should be measured at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest, using a stretch resistant tape. Hip circumference should be measured around the widest portion of the buttocks, with the tape parallel to the floor.

For both measurements: Participant should stand with feet close together, arms at the side and body weight evenly distributed, and should wear little clothing. The participant should be relaxed, and the measurements should be taken at the end of a normal expiration. Each measurement should be taken twice and entered here. If the difference between the two measurements exceeds 0.5 inches, the two measurements should be repeated.

Source: Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008.

Source: NHLBI Obesity Education Initiative, nhlbi.nih.gov

3.	Ent	er two waist circumference measurements (inches):	
	•	Measurement 1		(888 = not assessed)
	•	Measurement 2		(888 = not assessed)
4.	Ent	er two hip circumference measurements (in	ches):	
	•	Measurement 1		(888 = not assessed)
		Measurement 2		(888 = not assessed)

ALZHEIMER'S COORDINATING CENTER naccdata.org

Sec	tior	n 1 – Participant vital sigr	s and anthrop	ometrics		continued
5.		er two readings spaced at least c detailed instructions below.	ne minute apart fo	r each arm.		
	5a.	Participant blood pressure - Le	ft arm:			
	•	Reading 1	/	′ <u> </u>	(888/888= not assessed)	
		Reading 2	/	′ <u> </u>	(888/888= not assessed)	
	5b.	Participant blood pressure - Rig	ght arm:			
	•	Reading 1	/	′ <u> </u>	(888/888= not assessed)	
	•	Reading 2	/	′ <u> </u>	(888/888= not assessed)	
6.	Par	ticipant resting heart rate (pulse			(888 = not assessed)	

Visit #:

Steps for proper blood pressure measurement

STEP 1 - Properly prepare the participant:

Participant ID:

- Have the participant relax, sitting in a chair (feet on floor, back supported) for >5 minutes
- · The participant should avoid caffeine, exercise, and smoking for at least 30 minutes before measurement.

Form date:

- Ensure that participant has emptied his/her bladder.
- · Neither the participant nor the observer should talk during the rest period or during the measurement.
- Remove all clothing covering the location of cuff placement.
- · Measurements made while the participant is sitting or lying on an examining table do not fulfill these criteria.

STEP 2 - Use proper technique for BP measurements

- Use a BP measurement device that has been validated and ensure that the device is calibrated periodically.
- Support the participant's arm (e.g., have it resting on a desk).
- Position the middle of the cuff on the participant's upper arm at the level of the right atrium (midpoint of the sternum).
- Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger- or smaller-than-normal cuff size is used.
- Either the stethoscope diaphragm or bell may be used for auscultatory readings.

STEP 3 - Take proper measurements

- Take two BP readings in both arms.
- Separate the second set of measurements from the first by one minute.
- For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP. Inflate the cuff 20-30 mm Hg above this level for an auscultatory determination of the BP level.
- For auscultatory readings, deflate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.

STEP 4 - Properly document accurate BP readings

- Record SBP and DBP. If using the auscultatory technique, record SBP and DBP as onset of the first Korotkoff sound and disappearance of all Korotkoff sounds, respectively, using the nearest even number.
- · Record the two readings of SBP and DBP in the left arm, and the two readings of SBP and DBP in the right arm.

STEP 5 - Give BP readings and interpretation to the participants

It is recommended to provide participants with the SBP/DBP readings both orally, and in writing.

Source: Checklist for accurate measurement of BP adapted from AHA Guidelines, Whelton PK et al., Hypertension. 2018; 71: e13-e11.

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

UDSv4.0, Initial Visit Packet, Form B1: EVALUATION FORM—Vital Signs and Anthropometrics, January 2025

Page 2 of 2



Form B3: Unified Parkinson's Disease Rating Scale (UPDRS¹) - Motor Exam

ADRC:	PTID:	Form date: _	//	Visit #:	initials:
Language: ☐ 1 English ☐ 2 Spanish	Mode: ☐ 1 In-person ☐ 0 Not completed (reason):	Key (not completed reason):	94=Remote visit 95=Physical probler 96=Cognitive/behar 97=Other 98=Verbal refusal		
administered contributions track the deg additional clo For video-re Curr Protoc	NS: This form is to be completed by to <u>all</u> participants. Clinician should or explanations for the findings. The ree of parkinsonism over time. The Unrification and scoring instructions, secorded examples of administra Neurosci. 2009 Oct; Chapter 10:	record results as observed re is form is intended to 1) deter IPDRS is not intended to esta see UDS Coding Guideboo tion, see Perlmutter JS. A Unit10.1. doi: 10.1002/04	gardless of whether mine the degree o blish the presence k for Form B3. Ch ssessment of Pa 71142301.ns100	er there are non-p f parkinsonism o or absence of par eck only <u>one</u> box rkinson disease Is49.	oarkinsonian n any visit, and 2) rkinsonism. For per question. e manifestations.
	ional) If the clinician completes th box is checked, all items will default		d determines all i	tems are norma	ll, check this box. If
1. Speech	2 Monotone, slurre 3 Marked impairme 4 Unintelligible	ression, diction and/or volu ed but understandable; mod ent, difficult to understand.			
2 Slight but defini 3 Moderate hypor 4 Masked or fixed		mia, could be normal "poker ely abnormal diminution of nimia; lips parted some of th facies with severe or comple CIFY):	facial expression e time te loss of facial exp	oression; lips par	rted ¼ inches or more
3. Tremor	at rest				
3a. Face, lips	1 Slight and infrequence Mild in amplitude 3 Moderate in amp	e and persistent; or moderat slitude and present most of the cude and present most of the	the time	it only intermitte	ently present
3b. Right ha	1 Slight and infrequence of the state of the	e and persistent; or moderat olitude and present most of the cude and present most of the	the time	it only intermitte	ently present
3c. Left hand	1 Slight and infrequence of the state of the	uently present e and persistent; or moderat olitude and present most of the tude and present most of the CIFY):	the time	it only intermitte	ently present

1-Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153–163, 293–304. Reproduced by permission of the author.

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

3. Tremor at rest	continued
3d. Right foot	□ 0 Absent □ 1 Slight and infrequently present □ 2 Mild in amplitude and persistent; or moderate in amplitude, but only intermittently present □ 3 Moderate in amplitude and present most of the time □ 4 Marked in amplitude and present most of the time □ 8 Untestable (SPECIFY):
3e. Left foot	□ 0 Absent □ 1 Slight and infrequently present □ 2 Mild in amplitude and persistent; or moderate in amplitude, but only intermittently present □ 3 Moderate in amplitude and present most of the time □ 4 Marked in amplitude and present most of the time □ 8 Untestable (SPECIFY):
4. Action or postur	ral tremor of hands
4a. Right hand	□ 0 Absent □ 1 Slight; present with action □ 2 Moderate in amplitude, present with action □ 3 Moderate in amplitude with posture holding as well as action □ 4 Marked in amplitude; interferes with feeding □ 8 Untestable (SPECIFY):
4b. Left hand	 Absent Slight; present with action Moderate in amplitude, present with action Moderate in amplitude with posture holding as well as action Marked in amplitude; interferes with feeding Untestable (SPECIFY):
5. Rigidity (judged on passive move	ement of major joints with participant relaxed in sitting position; cogwheeling to be ignored)
5a. Neck	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):
5b. Right upper extremity	 Absent Slight or detectable only when activated by mirror or other movements Mild to moderate Marked, but full range of motion easily achieved Severe; range of motion achieved with difficulty Untestable (SPECIFY):
5c. Left upper extremity	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):
5d. Right lower extremity	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):

Form date: ____ / ___ / ___ __ Visit #:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

5. Rigidity (judged on passive move	ement of major joints with participant relaxed in sitting position; cogwheeling to be ignored) continued
5e. Left lower extremity	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):
6. Finger taps (participant taps thum	b with index finger in rapid succession)
6a. Right hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
6b. Left hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
7. Hand movemen (participant opens and	ts closes hands in rapid succession)
7a. Right hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
7b. Left hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
The second se	ng movements of hands novements of hands, vertically and horizontally, with as large an amplitude as possible, both hands simultaneously)
8a. Right hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
8b. Left hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):

Form date: ____ / ___ / ___ __ Visit #:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

9. Leg agility (participant taps heel on	the ground in rapid succession, picking up entire leg; amplitude should be at least 3 inches)
9a. Right leg	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
9b. Left leg	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
10. Arising from chair (participant attempts to rise from a straight-backed chair, with arms folded across chest)	□ 0 Normal □ 1 Slow; or may need more than one attempt □ 2 Pushes self up from arms of seat. □ 3 Tends to fall back and may have to try more than one time, but can get up without help □ 4 Unable to arise without help □ 8 Untestable (SPECIFY):
11. Posture	□ 0 Normal □ 1 Not quite erect, slightly stooped posture; could be normal for older person □ 2 Moderately stooped posture, definitely abnormal; can be slightly leaning to one side □ 3 Severely stooped posture with kyphosis; can be moderately leaning to one side □ 4 Marked flexion with extreme abnormality of posture □ 8 Untestable (SPECIFY):
12. Gait	 Normal Walks slowly; may shuffle with short steps, but no festination (hastening steps) or propulsion Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or propulsion Severe disturbance of gait requiring assistance Cannot walk at all, even with assistance Untestable (SPECIFY):
13. Posture stability (response to sudden, strong posterior displacement produced by pull on shoulders while participant erect with eyes open and feet slightly apart; participant is prepared)	□ 0 Normal erect □ 1 Retropulsion, but recovers unaided □ 2 Absence of postural response; would fall if not caught by examiner □ 3 Very unstable, tends to lose balance spontaneously □ 4 Unable to stand without assistance □ 8 Untestable (SPECIFY):
14. Body bradykinesia and hypokinesia (combining slowness, hesitancy, decreased arm swing, small amplitude, and poverty of movement in general)	□ 0 None □ 1 Minimal slowness, giving movement a deliberate character; could be normal for some persons; possibly reduced amplitude □ 2 Mild degree of slowness and poverty of movement which is definitely abnormal; alternatively, some reduced amplitude □ 3 Moderate slowness, poverty or small amplitude of movement □ 4 Marked slowness, poverty or small amplitude of movement □ 8 Untestable (SPECIFY):
15. Total UPDRS Score (If one or more items are chec "8=Untestable", enter 888)	cked (0-108, 888)

Form date: ____ / ____ / ____ Visit #:



Form B4: CDR® Dementia Staging Instrument

PLUS NACC FTLD Behavior & Language Domains (CDR® Plus NACC FTLD)

ADRC:	PTID:	Form date://	Visit #:	initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired		
□1 English	□ 1 In-person	2=Too physically impaired		
☐2 Spanish	☐2 Remote (reason):	3=Homebound or nursing home		
	□1 Telephone □2 Video	4=Refused in-person visit		
		5=Other		

INSTRUCTIONS: This form is to be completed by the clinician or other trained health professional, based on co-participant report and behavioral and neurological exam of the participant. In the extremely rare instances when no co-participant is available, the clinician or other trained health professional must complete this form using all other available information and his/her best clinical judgment. Score only as decline from previous level due to cognitive loss, not impairment due to other factors, such as physical disability. For information on the required online CDR training, see the **UDS Coding Guidebook** for Form **B4**.

Section 1 - CDR® Dementia Staging Instrument¹

Impairment					
Please enter scores (below):	None = 0	Questionable = 0.5	Mild = 1	Moderate = 2	Severe = 3
1. Memory	No memory loss, or slight inconsistent forgetfulness	Consistent slight forgetfulness; partial recollection of events; "benign" forgetfulness	ilness; partial more marked for recent tion of events; events; defect interferes		Severe memory loss; only fragments remain
2. Orientation	Fully oriented	Fully oriented except for slight difficulty with time relationships	Moderate difficulty with time relationships; oriented for place at examination; may have geographic disorientation elsewhere	Severe difficulty with time relationships; usually disoriented to time, often to place	Oriented to person only
3. Judgment & Problem Solving	Solves everyday problems, handles business and financial affairs well; judgment good in relation to past performance	Slight impairment in solving problems, similarities, and differences	Moderate difficulty in handling problems, similarities, and differences; social judgment usually maintained	Severely impaired in handling problems, similarities, and differences; social judgment usually impaired	Unable to make judgments or solve problems
4. Community Affairs	Independent function at usual level in job, shopping, volunteer and social groups	Slight impairment in these activities	Unable to function independently at these activities, although may still be engaged in some; appears normal to casual inspection	No pretense of independent function outside the home; appears well enough to be taken to functions outside the family home	No pretense of independent function outside the home; appears too ill to be taken to functions outside the family home
5. Home & Hobbies	Life at home, hobbies, and intellectual interests well maintained	Life at home, hobbies, and intellectual interests slightly impaired	Mild but definite impairment of function at home; more difficult chores abandoned; more complicated hobbies and interests abandoned	Only simple chores preserved; very restricted interests, poorly maintained	No significant function in the home
6. Personal Care • <u>0</u>	Fully capable of self-care (= 0)		Needs prompting	Requires assistance in dressing, hygiene, keeping of personal effects	Requires much help with personal care; frequent incontinence
7. CDR Sum o	of Boxes	·	8. Global CDR	·	

'Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43(11):2412-4, 1993. Copyright@ Lippincott, Williams & Wilkins. Reproduced by permission.

ALZHEIMER'S COORDINATING naccmail@uw.edu naccdata.org

Participant ID:	Form date: /	/ Visit #:	

Section 2 - NACC FTLD Behavior & Language Domains

Impairment					
Please enter scores (below):	None = 0	Questionable = 0.5	Mild = 1	Moderate = 2	Severe = 3
9. Behavior, Comportment, & Personality ²	Socially appropriate behavior	Questionable changes in comportment, empathy, appropriateness of actions	Mild but definite changes in behavior	Moderate behavioral changes, affecting interpersonal relationships and interactions in a significant manner	Severe behavioral changes, making interpersonal interactions all unidirectional
10. Language ³	No language difficulty, or occasional mild tip- of-the-tongue	Consistent mild word- finding difficulties; simplification of word choice; circumlocution; decreased phrase length; and/or mild comprehension difficulties	Moderate word-finding difficulty in speech; cannot name objects in environment; reduced phrase length and/or agrammatical speech and/or reduced comprehension in conversation and reading	Moderate to severe impairments in either speech or comprehension; has difficulty communicating thoughts; writing may be slightly more effective	Severe comprehension deficits; no intelligible speech

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

²Excerpted from the Frontotemporal Demential Multicenter Instrument & MR Study (Mayo Clinic, UCSF, UCLA, UW).
³Excerpted from the PPA-CDR: A modification of the CDR for assessing dementia severity in patients with primary progressive aphasia (Johnson N, Weintraub S, Mesulam MM),



Form B5: BEHAVIORAL ASSESSMENT – Neuropsychiatric Inventory Questionnaire (NPI-Q1)

ADRC: _	PTID: Form date: _	/_	/_		Vis	it #:		initial	::	
Langua □1 En □2 Sp	glish \square_1 In-person \square_2 Remote (reason): \square_2 Video \square_3 \square_4 \square	Key (remote reason): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other Key (not completed reason) 95=Physical problem 96=Cognitive/behavioral propriors of the proprior of t							em	
descri	INSTRUCTIONS : This form is to be completed by the clinician or other trained health professional based on co-participant interview, as described by the training video. (This is not to be completed by the participant as a paper-and-pencil self-report.) For information on NPI-Q Interviewer Certification, see UDS Coding Guidebook for Form B5 . Check only one box for each category of response.									
mem 0=No For e	Please answer the following questions based on <u>changes</u> that have occurred since the participant first began to experience memory (i.e., cognitive) problems. Select 1=Yes <u>only</u> if the symptom(s) has been present <u>in the last month</u>. Otherwise, select 0=No. (NOTE: for the UDS, please administer the NPI-Q to all participants.) For each item marked 1=Yes, rate the SEVERITY of the symptom (how it affects the participant): 1= Mild (noticeable, but not a significant change) 2= Moderate (significant, but not a dramatic change) 3= Severe (very									
mark	ed or prominent; a dramatic change)									
1. NP	ICO-PARTICIPANT: \square_1 Spouse \square_2 Child \square_3 Other (SPECIFY):							SEVE	DITV	
			Yes	No	Unk		Mild	Mod		Unk
2.	Delusions – Does the patient have false beliefs, such as thinking that others are stealing from him/her or planning to harm him/her in some way?	2a.		О	□ 9	2b.		2	Пз	□ 9
3.	Hallucinations – Does the patient have hallucinations such as false visions or voices? Does he or she seem to hear or see things that are not present?	3a.		О	<u> </u>	3b.		□ 2	□ 3	<u> </u>
4.	Agitation/Aggression – Is the patient resistive to help from others at times, or hard to handle?	4a.	□ 1	О	<u> </u>	4b.	□ 1		□ 3	<u> </u>
5.	Depression/Dysphoria – Does the patient seem sad or say that he/ she is depressed?	5a.	□ 1	О	<u> </u>	5b.	□ 1	2	□ 3	<u> </u>
6.	Anxiety – Does the patient become upset when separated from you? Does he/she have any other signs of nervousness such as shortness of breath, sighing, being unable to relax, or feeling excessively tense?	6a.	□ ₁	По	<u> </u>	6b.	□ ₁	□ ₂	Пз	□ 9
7.	Elation/Euphoria – Does the patient appear to feel too good or act excessively happy?	7a.	□ 1	О	□ 9	7b.	□ 1	2	Пз	□ 9
8.	Apathy/Indifference – Does the patient seem less interested in his/her usual activities or in the activities and plans of others?	8a.	□ 1	О	<u> </u>	8b.	□ 1	□ 2	□ 3	<u> </u>
9.	Disinhibition – Does the patient seem to act impulsively, for example, talking to strangers as if he/she knows them, or saying things that may hurt people's feelings?	9a.		О	□ 9	9b.	□ 1	\square_2	Пз	□ 9
10.	Irritability/Lability – Is the patient impatient and cranky? Does he/she have difficulty coping with delays or waiting for planned activities?	10a.	□ 1	О	<u></u> 9	10b.	□ 1	□ 2	Пз	<u></u> 9
11.	Motor disturbance – Does the patient engage in repetitive activities such as pacing around the house, handling buttons, wrapping string, or doing other things repeatedly?	11a.	□ 1	О	□ 9	11b.		□ 2	Пз	<u></u> 9
12.	Nighttime behaviors – Does the patient awaken you during the night, rise too early in the morning, or take excessive naps during the day?	12a.	□ 1	По	9	12b.		□ 2	□ 3	<u></u> 9
	Appetite/Eating – Has the patient lost or gained weight, or had a change in the type of food he/she likes?	13a.	□ 1	О	<u> </u>	13b.	□ 1	2	□ 3	<u> </u>
Copyrig	nt© Jeffrey L. Cummings, MD. Reproduced by permission.									



Form B6: BEHAVIORAL ASSESSMENT - Geriatric Depression Scale (GDS)¹

ADRC: _	: PTID: Form date://			_/	Visit #:	initials:				
□1 Eng	Language: ☐ 1 English ☐ 2 Spanish ☐ 2 Not completed (reason): ☐ 2 Video ☐ 0 Not completed (reason): ☐ 5 Cother Mode:				npaired 95=Physical problem nursing home 96=Cognitive/behavioral proble					
	INSTRUCTIONS : This form is to be completed by the clinician or other trained health professional, based on participant response. For additional clarification and examples, see UDS Coding Guidebook for Form B6 . Check only <u>one</u> answer per question.									
	Check this box and enter "88" below for the Total GDS Score if and only if the participant: 1.) does not attempt the GDS, or 2.) answers fewer than 12 questions.									
Instruct the participant : "In the next part of this interview, I will ask you questions about your feelings. Some of the questions I will ask you may not apply, and some may make you feel uncomfortable. For each question, please answer "yes" or "no," depending on how you have been feeling in the past week, including today ."										
				Yes	No	Did not answer				
1.	Are you basically satisfied with your life?			О	□ 1	9				
2.	2. Have you dropped many of your activities and interests?			□ 1	О	<u></u> 9				
3.	3. Do you feel that your life is empty?			□ ₁	□ ₀	9				
4.	4. Do you often get bored?			□ 1	□ ₀	<u> </u>				
5.	Are you in good spirits most of the time?			По	□ 1	<u> </u>				
6.	Are you afraid that something bad is goir	ng to happen to you?		□ 1	□ ₀	<u> </u>				
7.	Do you feel happy most of the time?			По	□ 1	9				
8.	Do you often feel helpless?			□ ₁	\square_0	<u> </u>				
9.	Do you prefer to stay at home, rather than	n going out and doing ne	w things?	□ ₁	\square_0	<u> </u>				
10.	Do you feel you have more problems with	h memory than most?		□ 1	\square_0	<u> </u>				
11.	Do you think it is wonderful to be alive no	ow?		По	□ 1	<u> </u>				
12.	Do you feel pretty worthless the way you	are now?		□ ₁	□ ₀	<u> </u>				
13.	Do you feel full of energy?			По	□ 1	<u> </u>				
14.	Do you feel that your situation is hopeles	s?		□ ₁	□ ₀	<u></u> 9				
15.	Do you think that most people are better	off than you are?		□ 1	О	<u></u> 9				
16.	Sum all checked answers for a Total GDS :	Score (max score = 15; did l	not complete	= 88)						

15heikh Jl, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clinical Gerontology: A Guide to Assessment and Intervention 165–173, NY: The Haworth Press, 1986. Reproduced by permission of the publisher.

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org



Form B7: FUNCTIONAL ASSESSMENT – NACC Functional Assessment Scale (FAS1)

ADRC:	PTID:	Form date://	Visit #: initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired	Key (not completed reason):
☐1 English	□ 1 In-person	2=Too physically impaired	95=Physical problem
☐2 Spanish	☐ 2 Remote (reason):	3=Homebound or nursing home	96=Cognitive/behavioral problem
	☐ 1 Telephone ☐ 2 Video	4=Refused in-person visit	97=Other
	□ o Not completed (reason):	5=Other	98=Verbal refusal

INSTRUCTIONS: This form is to be completed by the clinician or other trained health professional, based on information provided by the co-participant. For further information, see <u>UDS Coding Guidebook for Form B7</u>. Indicate the level of performance for each activity by checking the one appropriate response.

In the past four weeks, did the participant have difficulty or need help with:	Not applicable (e.g., never did)	Normal	Has difficulty, but does by self	Requires assistance	Dependent	Unknown
1. Writing checks, paying bills, or balancing a checkbook	□8	О	□ 1	□ 2	□ 3	<u></u> 9
2. Assembling tax records, business affairs, or other papers	□8	О	□ 1	\square_2	□ 3	<u></u> 9
3. Shopping alone for clothes, household necessities, or groceries	□8	О	<u> </u>	<u>2</u>	□ 3	<u></u> 9
4. Playing a game of skill such as bridge or chess, working on a hobby	□8	О	□ 1	<u></u>	3	<u></u> 9
5. Heating water, making a cup of coffee, turning off the stove	□8	О	□ 1	□ 2	Пз	<u></u> 9
6. Preparing a balanced meal	□8	О	□ 1	\square_2	□ 3	9
7. Keeping track of current events	□8	О	□ 1	2	Пз	<u></u> 9
8. Paying attention to and understanding a TV program, book, or magazine	□8	□0	□ 1	□ ₂	□ 3	□ 9
9. Remembering appointments, family occasions, holidays, medications	□ 8	□0	<u> </u>	□ ₂	□ 3	<u></u> 9
10. Traveling out of the neighborhood, driving, or arranging to take public transportation	□8	□0	□ 1	\square_2	□ ₃	□ 9

'Adapted from table 4 of Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities of older adults in the community. J Gerontol 37:323 – 9, 1982. Copyright© $1982. \, The \, Gerontological \, Society \, of \, America. \, Reproduced \, by \, permission \, of \, the \, publisher. \,$

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org



Form B8: EVALUATION FORM – Neurological Examination Findings

ADRC: _	PTID:	Fo	orm date:	//\	Examir isit #: initials:						
Languag □1 Eng □2 Spa	lish	(remote reaso	3=Homeboo	itively impaired ically impaired und or nursing home n-person visit							
assessii experie	INSTRUCTIONS: This form should be completed by a clinician with experience in performing a comprehensive neurologic examination, assessing the presence/absence of neurological signs, and rating the degree of any abnormalities. Additionally, the clinician should have experience in completing each of the assessment measures associated with the gateway questions if any key neurologic findings are present. For additional clarification and examples, see UDS Coding Guidebook for Form B8. Check only one box per question.										
Secti	on 1 – Examiner & examination quest	tions									
	 Which of the following was completed on this participant? 0 No neurologic examination (END FORM HERE) 1 Comprehensive neurologic examination as suggested in the UDS Coding Guidebook 2 Focused or partial neurologic examination performed in-person 3 Focused or partial neurologic examination performed via video 										
	/ere there abnormal neurological exam finding ☐ No abnormal findings (END FORM HERE; /f thi. ☐ 1 Yes		ed, all items will c	default to 0 = Absent in	the database)						
Secti	on 2 – Specific clinical findings										
Secti	ion 2A – Parkinsonian signs										
in											
FIND	ING:	Absent	Focal or Unilateral	Bilateral & Largel Symmetric	y Bilateral & Largely Asymmetric	Not Assessed					
3a.	Slowing of fine motor movements	По	1	\square_2	□ 3	□8					
3b.	Limb tremor at rest	По	□ 1	\square_2	□ 3	□8					
3с.	Limb tremor - postural	□о	□ 1	\square_2	3	□8					
3d.	Limb tremor - kinetic	По	□ 1	\square_2	3	□8					
3e.	Limb rigidity - arm	О	□ 1	\square_2	3	□8					
3f.	Limb rigidity - leg	О	□ 1	\square_2	3	□8					
3g.	Limb dystonia - arm	□ ₀	□ 1	\square_2	3	□8					
3h.	Limb dystonia - leg	□ ₀	□ 1	\square_2	3	□8					
3i.	Chorea	О	□ 1	\square_2	□3	□8					

ALZHEIMER'S COORDINATING CENTER naccdata.org

Secti	on 2 – Specific clinical findings						C	ontinued
Secti	on 2A – Parkinsonian signs							
FIND	FINDING: Absent Present Not Asses:							
3j.	Decrement in amplitude of fine motor movem	nents			По	□ 1		38
3k.	Axial rigidity				О	<u></u> 1		_8
3l.	Postural instability				По	□ 1		3 8
3m.	Facial masking				О	<u></u> 1		3 8
3n.	Stooped posture				По	□ 1		3 8
Secti	on 2B – Cortical/pyramidal/other signs							
 4. O No abnormal signs in this section are present (SKIP TO SECTION 2C; If this box is checked, Q4a through Q4q will default to 0=Absent in the database) 1 Yes (IF YES – complete questions 4a–4q and consider completing additional measures as described on page 3) 8 Not assessed (SKIP TO SECTION 2C; If this box is checked, Q4a through Q4q will default to 8 = Not Assessed in the database) 								
FIND	NG:	Absent	Focal or Unilateral		l & Largely metric	Bilateral & Asymm		Not Assessed
4a.	Limb apraxia	О	1					
4b.	Face or limb findings in UMN distribution*	По	1	[\square_2	□ ₃		□8
4c.	Face or limb findings in an LMN distribution*	По	□ ₁	[□8
4d.	Visual field cut	По	<u></u> 1	[2	3		□8
4e.	Limb ataxia	О	□ 1	[2	3		□8
4f.	Myoclonus	□ ₀	□ 1	\square_2		Пз		□8
FIND	NG:				Absent	Present	Not A	ssessed
4g.	Unilateral Somatosensory loss (localized to the b localized to the spinal cord or peripheral nerves)	rain; disregar	d sensory chang	es	О	□ ₁	[3 8
4h.	Aphasia (disregard complaints of mild dysnomia if not viewe	ed as reflecting	a clinically significa	ant change)	О	□1		8
4i.	Alien limb phenomenon				О	□1		8
4j.	Hemispatial neglect				О	□ 1		8
4k.	Prosopagnosia				О	□ ₁		3 8
41.	Simultanagnosia				О	□ ₁		8
4m.	n. Optic ataxia					□1		8
4n.	n. Apraxia of gaze					□ 1		8
40.	Vertical +/- horizontal gaze palsy**				□ ₀			8
4p.	Dysarthria*				□ ₀	□ ₁		□ 8
4q.	Apraxia of speech				О	□1		8
	ndings could include weakness in a pyradmidal pa ndings could include weakness due to neuromuscu							as

Form date:

Visit #:

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

**Do not mark Present if only reduction of upgaze is present.

could be consistent with a cerebrovascular insult or with a degenerative disorder such as ALS, PLS, SMA, PSP, CBS, etc.

Participant ID: Form date:	_ / / Visit #:
Section 2 – Specific clinical findings Section 2C – Gait	continued
5. O No abnormal signs in this section are present (END FOF 1 Yes (IF YES - complete question 5a and consider completing add 8 Not assessed (END FORM HERE)	
5a. Finding: ☐ 1 Hemiparetic gait (spastic) ☐ 2 Foot drop gait (lower motor neuron) ☐ 3 Ataxic gait ☐ 4 Apractic magnetic gait ☐ 5 Hypokinetic/parkinsonian gait ☐ 6 Antalgic gait	☐ 7 Other (SPECIFY):
Section 2D – Additional measures	
There are several additional clinical measures to consider for completion depending on the findings and the suspicion of the clinical syndrome; these include, but are not limited to, the following: a) If there are any features of a movement disorder (e.g., bradykinesia, tremor, rigidity, postural instability, etc.): Consider completing Form B3 UPDRS, or the MDS-UPDRS b) If there are any features of ALS (e.g., upper motor neuron dysfunction and/or lower motor neuron dysfunction): Consider completing the ALSFRS-R c) If there are any features of PSP- Richardson's syndrome (e.g., parkinsonism, postural instability, supranuclear gaze palsy, etc.): Consider completing the PSPRS	d) If there are any features of corticobasal syndrome (e.g., limb rigidity, limb apraxia, myoclonus, dystonia, corticol sensory loss, alien limb phenomenon, etc.): Consider completing the PSPRS and/or the CBFS e) If there are any features of complex visual processing dysfunction (e.g. hemineglect, visual agnosia, simultanagnosia, optic ataxia, ocular apraxia, apraxia of eyelid opening, etc.): Consider completing a standardized measure assessing PCA f) If there are any features of aphasia or apraxia of speech (e.g., NIH Stroke Scale, Progressive Aphasia Severity Scale, Western Aphasia Battery, etc.): Consider completing a standardized measure assessing speech and language g) If there are clinical and/or imaging findings suggesting a vascular contribution to the clinical presentation: Consider completing NIH Stroke Scale, Hachinski Ischemic Scale, etc.
Section 2E – Glossary of abbreviations	
ALS = Amyotrophic Lateral Sclerosis	
ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale	e-Revised
CBS = Corticobasal Syndrome	
CBFS = Cortical Basal ganglia Functional Scale	
LMN = Lower Motor Neuron	
MDS-UPDRS = Movement Disorders Society - Unified Parkinson's	Disease Ratina Scale
PCA = Posterior Cortical Atrophy	Discuse nating scare
PLS = Primary Lateral Sclerosis	
PSP = Progressive Supranuclear Palsy	
PSPRS = Progressive Supranuclear Palsy Rating Scale	
SMA = Spinal Muscular Atrophy	
UMN = Upper Motor Neuron	
UPDRS = Unified Parkinson's Disease Rating Scale	



Form B9: Clinician Judgment of Symptoms

ADRC:	PTID:		Visit #:		kaminer's iitials:	
□1 Er	Guage: English Spanish Mode: □ 1 In-person □ 2 Remote (reason): □ 3=Homebound or nursing home □ 1 Telephone □ 2 Video Spanish □ 1 Telephone □ 2 Video Spanish Spani					
or co- estim	PUCTIONS: This form is to be completed by participant. For all questions the clinician ate when symptoms began based on infor DS Coding Guidebook for Form B9. Che	must use their best judgment about whet mation from participant and co-participo	her sympto	ms are pre	sent and	make their
Sect	ion 1 – Changes across domains					
_	ted by participant					
	Does the <u>participant</u> report a decline in a baseline prior to onset of current syndrome,		0 No 1 Yes			e assessed / impaired
	Does the <u>participant</u> report a change in a baseline prior to onset of current syndrome	· ·	0 No 1 Yes			e assessed/ impaired
	3. Does the <u>participant</u> report the development of any significant neuropsychiatric/behavioral symptoms (relative to stable baseline prior to onset of current syndrome)?					e assessed/ impaired
Repoi	ted by co–participant					
	Does the <u>co-participant</u> report a decline i stable baseline prior to onset of current synd	, -	0 No 1 Yes	□8 The	ere is no c	o-participant
5.	Does the <u>co-participant</u> report a change i baseline prior to onset of current syndrome,	•	0 No 1 Yes	□8 The	ere is no c	o-participant
	Does the <u>co-participant</u> report the develoneuropsychiatric/behavioral symptoms (rof current syndrome)?		□ 0 No □ 1 Yes	□8 The	ere is no c	o-participant
Repoi	ted by clinician					
	Does the participant have any neuropsycl cognitive domains, or changes in any mot		nny	□0 No □1 Yes		RM HERE)
	following sections record the phenotypmined by the clinician's best judgment fol					
Sect	ion 2 – Cognitive impairment					
Cons	der if the participant currently is meaning	ıfully impaired, <u>relative to stable baseli</u> ı	ne prior to	onset of o	urrent s	yndrome:
	Based on the clinician's judgment, is the pairment in cognition?	participant currently experiencing meani	ngful	□o No □1 Yes		QUESTION 11)
9.	ndicate whether the participant is meani	ngfully impaired in the following cogniti	ve domains	or has flu	ctuating	cognition:
	gnitive			No	Yes	Unknown
	 Memory — Does the participant forge statements, or misplace things more th 		is or	□ ₀	□ 1	<u></u> 9
9b	Orientation — Does the participant he forget names of people they know wel familiar locations?	ave trouble knowing the day, month, and I, get lost in familiar locations, or not reco		□0	□ 1	<u></u> 9
90		ing, and problem–solving) — Does the estike trips, financial transactions, partie		По	□ 1	<u></u> 9

Soction	on 2 – Cognitive impairment			continued
Secu	on 2 – Cognitive impairment	DI.	V.	
9d.	Language — Does the participant have hesitant speech, have trouble finding words, use inappropriate words without self-correction, or have trouble with speech comprehension?	No	Yes	Unknown
9e.	Visuospatial function — Does the participant have difficulty interpreting visual stimuli or finding their way around in familiar environments?	По	□ 1	9
9f.	Attention/concentration — Does the participant have a short attention span or limited ability to concentrate? Are they easily distracted?	□o	□ 1	9
9g.	Fluctuating cognition — Does the participant exhibit pronounced variation in attention and alertness, noticeably over hours or days—for example, long lapses or periods of staring into space, or times when their ideas have a disorganized flow?	По	□ ₁	<u></u> 9
9h.	Other (SPECIFY):	О	□ 1	
9i.	If any of the cognitive symptoms in 9a-9h are present, at what age did they begin? (The clinician must use their best judgment to estimate an age of onset. If multiple symptoms with different ages of onset are identified, denote the age of the earliest symptom.)			
lr is	Indicate the mode of onset for the most prominent cognitive problem that a causing the participant's complaints and/or affecting the participant's abrupt curvaint.		ner (SPEC nknown	IFY):
Section	on 3 – Neuropsychiatric symptoms and behavioral changes			
Consid <u>relativ</u>	er if the participant manifests – <i>in the last month</i> – clinically meaningful neuropsychiatric synetos is the current syndrom of the curr			
	ased on the clinician's judgment, does the participant manifest clinically meaningful europsychiatric symptoms or meaningful change in behavior?	□o No □1 Yes		QUESTION 14)
	pecify the phenotype of clinically meaningful neuropsychiatric symptoms or meaningful cha nanifested in the last month .	nge in be	havior th	at has
Mood	, motivation, and agitation	No	Yes	Unknown
12a.	Apathy/withdrawal — Has the participant lost interest in the world around them, lost interest in doing things, or lack motivation for starting new activities?	По	□ 1	□ 9
12b.	Depressed mood — Does the participant seem sad or depressed, or say that they feel sad or depressed?	\square_0	□ 1	<u>9</u>
12c.	Anxiety — Does the participant seem very nervous, worried, or frightened for no apparent reason? Do they seem very tense or fidgety? Do they seem afraid to be apart from caregivers or from others that they trust?		<u></u> 1	<u></u> 9
12d.	d. Euphoria — Does the participant seem too cheerful or too happy for no reason, manifest a persistent and abnormally good mood, or find humor where others do not?		□ 1	<u>9</u>
12e.	Irritability — Does the participant get irritated and easily disturbed? Are their moods very interchangeable? Are they abnormally impatient?	По	□ 1	□ 9
12f.	2f. Agitation — Is the participant easily distressed or angered, or hard to handle, or uncooperative, or resistive to care or to help from others?			<u></u> 9
12g.	If any of the mood–related behavioral changes in 12a–12f are present, at what age did they begin? (The clinician must use their best judgment to estimate an age of onset. If multiple symptoms are identified, denote the age of the earliest symptom.)		-—	

Form date: ____ / ___ / ___ __ __ __

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Particip	ant ID:	Form 0	late:	/	/	Visit #: _		
Section 3 – Neuropsychiatric symptoms and behavioral changes continued.								
Psych	Psychosis and impulse control							Unknown
12h.	Visua stimu	al hallucinations - Does the participar ılus?	nt exhibit visua	al perception	ns without a	О	□ 1	<u> </u>
1	2h1.	IF YES, do their hallucinations includ as pixelation of flat uniform surfaces?	•	at are not de	finite objects, such	О	□ 1	<u> </u>
1	2h2.	IF YES, do their hallucinations includ or people, either as independent image.				О	□ 1	<u> </u>
12i.	Audi	tory hallucinations - Does the partici llus?	oant exhibit a	uditory perc	eptions without a	О	□ 1	9
	12i1.	IF YES, do the auditory hallucination simple sounds?	s include simp	ole sounds li	ke knocks or other	О	□ 1	<u> </u>
	12i2.	IF YES, do the auditory hallucination words, or music?	s include com	plex sounds	like voices speaking	О	□ 1	9
12j.	exam	sions - Does the participant have fixed ple, insisting that others are trying to family members or staff are not who the?	harm them or	steal from tl	nem? Have they said	По	□ 1	<u></u> 9
12k.		ession — Does the participant shout are, or exhibit other verbally or physicall			ot to hit or hurt	□о	□ 1	<u> </u>
12l.	prese	of the psychosis and impulse controlent, at what age did they begin? (<i>The clee of onset. If multiple symptoms are iden</i>	inician must u	se their best j	udgment to estimate			
Person	nality	,				No	Yes	Unknown
12m.	are n	shibition — Does the participant act in ot usually done or said in public, or do rs, or do they talk personally to strange	things that ar	e embarrass	ing to caregivers or	О	□ 1	□ 9
12n.	Pers	onality change — Does the participar	nt exhibit bizaı	rre behavior	or behavior			

	-	ent, at what age did they begin? (The clinician must use their best judgme ge of onset. If multiple symptoms are identified, denote the age of the earlie					
Perso	ersonality						Unknown
12m.	Disinhibition — Does the participant act impulsively without thinking, say things that are not usually done or said in public, or do things that are embarrassing to caregivers or others, or do they talk personally to strangers or have disregard for personal hygiene?					□ 1	<u></u> 9
12n.	Personality change — Does the participant exhibit bizarre behavior or behavior uncharacteristic of the participant, such as unusual collecting, suspiciousness (without delusions), unusual dress, or unusual eating behaviors?				□0	□ 1	<u></u> 9
12o.	Loss	of empathy — Does the participant fail to take others' feelings into ac	count?		О	□ 1	<u> </u>
12p.	• Obsessions and/or compulsions — Does the participant repeatedly and excessively focus on particular ideas or activities, or have they developed new habits, like physical behaviors or stereotypical verbal phrases?				□ ₀	□ 1	<u></u> 9
12q.	Explosive anger — Does the participant have a "short fuse"? Do they display explosive outbursts of anger or rage?				□o	□ 1	<u> </u>
12r.	Substance use — Does the participant currently show evidence of excessive consumption of recreational, psychoactive, or typically abused substances (substantial increase compared with prior habits, and beyond medical necessity if prescribed substance)?					□ 1	<u> </u>
	12r1.	IF YES, record substance(s) involved: (Check all that apply)	12r1b. [12r1c. [12r1d. [12r1e. [1 Se 1 0 1 Ce	cohol edative/h piate ocaine annabis ther (SPE	, ·	
12s.	did t	of the personality–related behavioral changes in 12m–12r are present they begin? (The clinician must use their best judgment to estimate an age iple symptoms are identified, denote the age of the earliest symptom.)		ge			

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Sec	tion 3 – Neuropsychiatric symptoms and behavioral changes			continued	
REM	l sleep	No	Yes	Unknown	
12	t. REM sleep behavior disorder — While sleeping, does the participant appear to repeatedly act out their dreams (e.g., punch or flail their arms, shout, or scream)?	О		<u></u> 9	
	12t1. IF YES, at what age did the dream enactment behavior begin? (The clinician must use their best judgment to estimate an age of onset.)				
	12t2. Was REM sleep behavior disorder confirmed by polysomnography?	□ ₀	□ 1	<u> </u>	
Oth	er	No	Yes	Unknown	
12	Other behavioral changes (SPECIFY):	□ ₀	□ 1		
13.	Overall mode of onset for behavioral changes: Indicate the mode of onset for the most prominent behavioral problem 2 Subacute	□4 Otl	ner (SPEC	IFY):	
	that is causing the participant's complaints and/or affecting the participant's function.	□99 Ur	nknown		
Sec	tion 4 – Motor changes				
	ider if the participant currently has meaningful change in motor function <u>that represents a c</u> line prior to the current syndrome and is potentially due to a disorder affecting the cent				
14.	Based on the clinician's judgment, is the participant currently experiencing any meaningful changes in motor function?	□o No		QUESTION 19)	
15.	Indicate whether the participant has meaningful change in motor function:				
Mot	or	No	Yes	Unknown	
15	Gait disorder — Has the participant's walking changed, not specifically due to arthritis, injury, or peripheral neuropathy? Are they unsteady, or do they shuffle when walking, have little or no arm-swing, or drag a foot?	□о	<u></u> 1	<u></u> 9	
15	Falls — Has the participant had an increase in frequency of falls compared with their stable baseline prior to the current syndrome?	О	□ 1	<u>9</u>	
15	Slowness — Has the participant noticeably slowed down in walking, moving, or writing by hand, other than due to an injury or illness?	О	□ 1	<u>9</u>	
150	Tremors — Has the participant had rhythmic shaking, especially in the hands, arms, legs, head, mouth, or tongue?	□ ₀	□ 1	<u>9</u>	
15	Limb weakness — Has the participant noticed a change (abrupt or gradual) in limb function such that an arm and/or leg is weak compared to their prior baseline?	□ ₀	□ 1	<u>9</u>	
15	f. Change in facial expression — Has the participant's facial expression changed or become more "wooden," or masked and unexpressive?	О	□ 1	<u></u> 9	
15	Change in speech — Has the participant noted a change in speech (abrupt or gradual) such that speech is slurred, or the ability to articulate the tongue and lips to form words and sentences has declined compared to their baseline?	□0	□ 1	<u></u> 9	
15	15h. If changes in motor function are present in 15a–15g, at what age did they begin? (The clinician must use their best judgment to estimate an age of onset. If multiple symptoms are identified, denote the age of the earliest symptom.)				
16. Mode of onset for motor changes: Indicate the mode of onset for the most prominent motor problem that is causing the participant's complaints and/or affecting the participant's function. ☐ 1 Gradual ☐ 2 Subacute ☐ 3 Abrupt			ner (SPEC	IFY):	
			nknown		
		No	Yes	Unknown	
17.	Were changes in motor function suggestive of parkinsonism?	О	□ 1	<u></u> 9	
18.	Were changes in motor function suggestive of amyotrophic lateral sclerosis (ALS) (e.g., changes in muscle strength, or muscle twitches in one or more limbs, or slurred speech)?	□0	□ 1	<u></u> 9	

Form date: ____ / ___ / ____ ___ __

Sec	tion 5 – Overall course of decline and predominant domain	
19.	Overall course of decline of cognitive/behavioral/motor syndrome:	1 Gradually progressive 2 Stepwise 3 Static 4 Fluctuating 5 Improved 8 Not applicable 9 Unknown
20.	Indicate the <u>predominant</u> domain that was first recognized as changed in the participant:	1 Cognition 2 Behavior 3 Motor function 8 Not applicable

Participant ID: _____ Form date: ___ / ___ / ___ Visit #: __



Form C2: Neuropsychological Battery Scores

ADRC:	PTID:	Form date://	Visit #: initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired	
□1 English	□1 In-person	2=Too physically impaired	
☐2 Spanish	□₂ Remote (reason):	3=Homebound or nursing home	
	□₂ Video	4=Refused in-person visit	
		5=Other	

INSTRUCTIONS: This form is to be completed by ADRC or clinic staff. For test administration and scoring, see <u>Instructions for</u> Neuropsychological Battery, Form C2. Any new participants who enroll in the UDS after the implementation of UDSv4 must be assessed with the new neuropsychological test battery (Form C2 or C2T).

KEY: If the participant cannot complete any of the following exams, please give the reason by entering one of the following codes: 95 / 995 = Physical problem 96 / 996 = Cognitive/behavior problem 97 / 997 = Other problem 98 / 998 = Verbal refusal

Section 1 — Montreal Cognitive Assessment (MoCA)					
1a.	Was any part of the MoCA administered	? O No (If No, enter reason code, 95 – 98):			
1b.	MoCA was administered:	\Box 1 In ADRC or clinic \Box 2 In home \Box 3 In person	on — other		
1c.	Language of MoCA administration:	1 English 2 Spanish 3 Other (SPECIFY):			
1d.	Participant was unable to complete one	or more sections due to visual impairment:	□ o No □ 1 Yes		
1e.	Participant was unable to complete one	or more sections due to hearing impairment:	□ o No □ 1 Yes		
1f.	Total Raw Score — Uncorrected (Not corrected for education or visual/hearing (Enter 88 if any of the following MoCA items we	•	(0-30, 88)		
1g.	Visuospatial/executive — Trails		(0-1, 95-98)		
1h.	Visuospatial/executive — Cube		(0-1, 95-98)		
1i.	Visuospatial/executive — Clock contour		(0-1, 95-98)		
1j.	$\label{thm:linear_variation} \mbox{Visuospatial/executive} \mbox{Clock number}$	s	(0-1, 95-98)		
1k.	Visuospatial/executive — Clock hands		(0-1, 95-98)		
11.	Language — Naming		(0-3, 95-98)		
1m.	Memory — Registration (two trials)		(0-10, 95-98)		
1n.	Attention — Digits		(0-2, 95-98)		
10.	Attention — Letter A		(0-1, 95-98)		
1p.	Attention — Serial 7s		(0-3, 95-98)		
1q.	Language — Repetition		(0-2, 95-98)		
1r.	Language — Fluency		(0-1, 95-98)		
1s.	Abstraction		(0-2, 95-98)		
1t.	Delayed recall — No cue		(0-5, 95-98)		
1u.	Delayed recall — Category cue		(0-5; 88=Not applicable)		
1v.	Delayed recall — Recognition		(0-5; 88=Not applicable)		
1w.	Orientation — Date		(0-1, 95-98)		
1x.	Orientation — Month		(0-1, 95-98)		
1y.	Orientation — Year		(0-1, 95-98)		
1z.	Orientation — Day		(0-1, 95-98)		
1aa.	Orientation — Place		(0-1, 95-98)		
1bb.	Orientation — City		(0-1, 95-98)		

ALZHEIMER'S COORDINATING naccmail@uw.edu naccdata.org

Participa	nt ID: Form date: / / / Vi	isit #:
Sectio	n 2 — Administration of the remainder of the battery	
2a.	The tests following the MoCA were administered: 1 In ADRC or clinic 2 In home	☐3 In person — other
2b.	Language of test administration:	
Sectio	n 3 — Craft Story 21 Recall (Immediate)	
3a.	Total story units recalled, verbatim scoring	(0 –44, 95-98)
3b.	(If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 4a.) Total story units recalled, paraphrase scoring	(0-25)
	n 4 — Benson Complex Figure Copy	
	Total score for copy of Benson figure (If test not completed, enter reason code, 95–98)	(0 –17, 95-98)
	n 5 — Number Span Test: Forward	(0-17,93-90)
Section		
5a.	Number of correct trials (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 6a.)	(0-14, 95-98)
5b.	Longest span forward	(0, 3-9)
Sectio	n 6 — Number Span Test: Backward	
ба.	Number of correct trials (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 7a.)	(0 –14, 95-98)
6b.	Longest span backward	(0, 2-8)
Sectio	n 7 — Category Fluency	
7a.	Animals: Total number of animals named in 60 seconds (If test not completed, enter reason code, 95–98)	(0 –77, 95-98)
7b.	Vegetables: Total number of vegetables named in 60 seconds (If test not completed, enter reason code, 95–98)	(0 –77, 95-98)
Sectio	n 8 — Trail Making Test	
8a.	PART A: Total number of seconds to complete (if not finished by 150 seconds, enter 150) (If test not completed, enter reason code, 995–998, and SKIP TO QUESTION 8b.)	(0 –150, 995-998)
	8a1. Number of commission errors	(0-40)
	8a2. Number of correct lines	(0-24)
8b.	PART B: Total number of seconds to complete (if not finished by 300 seconds, enter 300) (If test not completed, enter reason code, 995–998, and SKIP TO QUESTION 9a.)	(0-300, 995-998)
	8b1. Number of commission errors	(0 -40)
	8b2. Number of correct lines	(0-24)
Sectio	n 9 — Benson Complex Figure Recall	
9a.	Total score for drawing of Benson figure following 10- to 15-minute delay (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 10a.)	(0 –17, 95-98)
9b.	Recognized original stimulus from among four options?	□ o No □ 1 Yes

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Participa	nt ID: / / V	isit #:
Sectio	n 10 — Craft Story 21 Recall (Delayed)	
10a.	Total story units recalled, verbatim scoring	
TUd.	(If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 11a.)	(0 –44, 95-98)
10b.	Total story units recalled, paraphrase scoring	(0-25)
10c.	Delay time (minutes) (99=Unknown)	(0 –85 minutes)
10d.	Cue ("boy") needed	□0 No □1 Yes
Sectio	n 11 — Verbal Fluency: Phonemic Test	
11a.	Number of correct F-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 11d.)	(0 -40, 95-98)
11b.	Number of F-words repeated in 1 minute	(0-15)
11c.	Number of non-F-words and rule violation errors in 1 minute	(0-15)
11d.	Number of correct L-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 12.)	(0-40, 95-98)
11e.	Number of L-words repeated in one minute	(0-15)
11f.	Number of non-L-words and rule violation errors in 1 minute	(0-15)
11g.	TOTAL number of correct F-words and L-words	(0-80)
11h.	TOTAL number of F-word and L-word repetition errors	(0-30)
11i.	TOTAL number of non-F/L words and rule violation errors	(0-30)
12. V	Which verbal learning test was 1 Rey AVLT	2 CERAD
	ddministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	(SKIP TO SECTION 14)
а	dministered? (COMPLETE SECTIONS 12 & 13,	(SKIP TO SECTION 14)
Sectio	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	(SKIP TO SECTION 14)
Sectio	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate)	(SKIP TO SECTION 14) # of intrusions
Section Total nu	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions	
Sectio Total nu Trial	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imper of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98)	# of intrusions
Section Total nu Trial Trial 1	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.)	# of intrusions 12b (No limit)
Section Total nu Trial Trial 1 Trial 2	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15)	# of intrusions 12b (No limit) 12d (No limit)
Sectio Total nu Trial Trial 1 Trial 2 Trial 3	in 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4	in 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5	in 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12i (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit)
Sectio Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6	COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit)
Sectio Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6	COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12i (0-15) 12i (0-15) 12i (0-15) 12i (0-15) 12m (0-15) 12m (0-15) 12m (0-15) Total delayed recall	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a.	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12l (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit) (0-15, 95-98)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a. 13b.	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12i (0-15) 12k (0-15) 12k (0-15) 12m (0-15) 12m (0-15) Total delayed recall (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) Intrusions	# of intrusions 12b
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a. 13b. 13c.	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall	# of intrusions 12b
Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a. 13b. 13c. 13d. 13e.	In 12 — Rey Auditory Verbal Learning (Immediate) Import of words correctly recalled and number of intrusions Total recall	# of intrusions 12b

NATIONAL ALZHEIMER'S COORDINATING CENTER | naccmail@uw.edu | naccdata.org

Sectio	n 14 — CERAD Verb	al Learning (Immediat	e)					
		umber of words correctly rec		r of intrusion	s			
Trial	Total recall	and a contest, real		Can't read		# of intrus	ions	
Trial 1	14a (0-10, 95-98) (If test was not completed, en	ter reason code, 95-98. SKIP TO C	QUESTION 16a.)	14b	_ (0-10)	14c		
Trial 2	14d (0-10)			14e	(0-10)	14f	(No limit)	
Trial 3	14g (0-10)			14h	_ (0-10)	14i	(No limit)	
Sectio	n 15 — CERAD Verb	al Learning (Delayed R	Recall and Rec	cognition)				
15a.	Delay time (minutes) (99	=Unknown)				(0-8	5 minutes)	
15b.		number of words correctly re eason code, 95-98, and SKIP TO C				(0-1	0, 95-98)	
15c.	J6 Word List Recall: Total	number of intrusions				(No l	imit)	
15d.	J7 Word List Recognition (If test not completed, enter r	: Total YES correct eason code, 95-98, and SKIP TO C	QUESTION 16a.)			(0-1	0, 95-98)	
15e.	J7 Word List Recognition	: Total NO correct				(0-1	0, 95-98)	
Sectio	n 16 — Multilingual	Naming Test (MINT)						
16a.	Total score (If test not completed, enter r	eason code, 95–98, and SKIP TO (QUESTION 17a)			(0-3	2, 95-98)	
16b.	Total correct without ser	nantic cue				(0-3	2)	
16c.	Semantic cues: Number	given				(0-3	2)	
16d.	Semantic cues: Number	correct with cue (88 = Not app	licable)			(0 –32, 88)		
16e.	Phonemic cues: Number	given				(0-32)		
16f.	Phonemic cues: Number	correct with cue (88 = Not app	plicable)			(0-3	2, 88)	
Sectio	n 17 — Overall appr	aisal						
17a.	17a. Per the clinician (e.g., neuropsychologist, behavioral neurologist, or other suitably qualified clinician), based on the UDS neuropsychological examination, the participant's cognitive status is deemed: 1 Better than normal for age 2 Normal for age 3 One or two test scores are abnormal 4 Three or more scores are abnormal or lower than expected 0 Clinician unable to render opinion							
Sectio	n 18 — Validity of p	articipant's response						
		vhether hearing or other fact ta analysis to know that such					ficult to judge, but	
18a.	How valid do you think the participant's responses are?	1 Very valid, probably ac 2 Questionably valid, po 3 Invalid, probably inacc	ssibly inaccurate	indication o	f particip	ant's cognitiv		
18b.	What makes this participant's responses less valid? 18b1.							

Form date: ____ / ___ / ___ __ __ __

Participant ID: ___



ADRC:	PTID:	Form date://	Examiner's Visit #: initials:			
Language 1 Englis 2 Spani	sh	Key (remote reason): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other				
Neurop assessed KEY: If	osychological Battery, Form C2T. Any neal with the new neuropsychological test bat the participant cannot complete any of t	he following exams, please give the reason by ente	nentation of UDSv4 must be			
Sectio	n 1 — Montreal Cognitive Asse	ssment (MoCA) Blind				
1a.	Was any part of the MoCA administered	d? \qquad 0 No (If No, enter reason code, 95 – 98). \qquad 1 Yes (CONTINUE WITH QUESTION				
1b.	Language of MoCA administration:	1 English ☐ 2 Spanish ☐ 3 Other (SPECIFY):				
1c.	Participant was unable to complete on	e or more sections due to hearing impairment:	□ o No □ 1 Yes			
1d.	Total Raw Score — Uncorrected (Not corrected for education or visual/hearin (Enter 88 if any of the following MoCA items w		(0-22, 88)			
1e.	Attention — Digits		(0 –2, 95-98)			
1f.	Attention — Letter A		(0-1, 95-98)			
1g.	Attention — Serial 7s		(0 –3, 95-98)			
1h.	Language — Repetition		(0 –2, 95-98)			
1i.	Language — Fluency		(0-1, 95-98)			
1j.	Abstraction		(0 –2, 95-98)			
1k.	Delayed recall — No cue		(0-5, 95-98)			
1l.	Delayed recall — Category cue		(0-5; 88=Not applicable)			
1m.	Delayed recall — Recognition		(0-5; 88=Not applicable)			
1n.	Orientation — Date		(0 –1, 95-98)			
10.	Orientation — Month		(0-1, 95-98)			
1p.	Orientation — Year		(0 –1, 95-98)			
1q.	Orientation — Day		(0-1, 95-98)			
1r.	Orientation — Place		(0-1, 95-98)			
1s.	Orientation — City		(0-1, 95-98)			
Section 2 — Administration of the remainder of the battery						
2a.	Language of test administration:	English 2 Spanish 3 Other (SPECIFY):	_			
Sectio	n 3 — Craft Story 21 Recall (Imi	mediate)				
3a.	Total story units recalled, verbatim scol (If test not completed, enter reason code, 95–9		(0 -44, 95-98)			
3b.	Total story units recalled, paraphrase so	coring	(0 –25)			

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

Participa	int ID:	Form date:		/isit #:
Sectio	on 4 — Number Span	Test: Forward		
4a.	Number of correct trials (If test not completed, enter r	eason code, 95–98, and SKIP T o	O QUESTION 5a.)	(0 –14, 95-98)
4b.	Longest span forward			(0, 3-9)
Sectio	n 5 — Number Span	Test: Backward		
5a.	Number of correct trials (If test not completed, enter r	eason code, 95–98, and SKIP T e	O QUESTION 6.)	(0 –14, 95-98)
5b.	Longest span backward			(0, 2-8)
6. W	hich verbal learning te	st was administered?	Rey AVLT (COMPLETE SECTIONS 6 & 13, SKIP SECTIONS 7 & 9)	2 CERAD (COMPLETE SECTIONS 7 & 9, SKIP SECTIONS 6 & 13)
Sectio	on 6 — Rey Auditory	Verbal Learning (Imi	mediate)	
		ecalled and number of intru		
Trial	,	Total recall		# of intrusions
Trial 1		6a (0-15, 95-98) (If test was not completed, en QUESTION 8a.)	ter reason code, 95-98, and SKIP TO	6b (No limit)
Trial 2		6c (0-15)		6d (No limit)
Trial 3		6e (0-15)		6f (No limit)
Trial 4		6g (0-15)		6h (No limit)
Trial 5		6i (0-15)		6j (No limit)
List B		6k (0-15)		6l (No limit)
Trial 6		6m (0-15)		6n (No limit)
Sectio	on 7 — CERAD Verba	Learning (Immediat	te)	
J4 Word	l List Memory Task: Total nu	umber of words correctly re	ecalled and number of intrusions	
Trial	Total recall			# of intrusions
Trial 1	7a (0-10, 95-98) (If test was not completed, en	ter reason code, 95-98. SKIP TC	O QUESTION 8a and LEAVE 9a-9e BLANK.)	7b (No limit)
Trial 2	7c (0-10)			7d (No limit)
Trial 3	7e (0-10)			7f (No limit)
Sectio	on 8 — Category Flue	ency		
8a.	Animals: Total number o	f animals named in 60 secc eason code, 95–98)	onds	(0 –77, 95-98)
8b.	Vegetables: Total number (If test not completed, enter r	er of vegetables named in 6 eason code, 95–98)	50 seconds	(0 -77, 95-98)

Sectio	n 9 — CERAD Verbal Learning (Delayed Recall and Recognition)	
9a.	Delay time (minutes) (99=Unknown)	(0 –85 minutes)
9b.	J6 Word List Recall: Total number of words correctly recalled (If test not completed, enter reason code, 95-98, and SKIP TO QUESTION 9d.)	(0 -10, 95-98)
9c.	J6 Word List Recall: Total number of intrusions	(No limit)
9d.	J7 Word List Recognition: Total YES correct (If test not completed, enter reason code, 95-98, and SKIP TO QUESTION 10a.)	(0-10, 95-98)
9e.	J7 Word List Recognition: Total NO correct	(0-10, 95-98)
Sectio	n 10 — Oral Trail Making Test (Optional)	
10a.	PART A: Total number of seconds to complete (if not finished by 100 seconds, enter 100) (If test not completed, enter reason code, 995–998. If test was skipped because optional, enter 888. SKIP TO QUESTION 10b.)	(0 -100, 888, 995-998)
	10a1. Number of commission errors	(No limit)
	10a2. Number of correct lines	(0-25)
10b.	PART B: Total number of seconds to complete (if not finished by 300 seconds, enter 300) (If test not completed, enter reason code, 995–998. If test was skipped because optional, enter 888. SKIP TO QUESTION 11a.)	(0-300, 888, 995-998)
	10b1. Number of commission errors	(No limit)
	10b2. Number of correct lines	(0-25)
Sectio	n 11 — Craft Story 21 Recall (Delayed)	
11a.	Total story units recalled, verbatim scoring (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 12a.)	(0-44, 95-98)
11b.	Total story units recalled, paraphrase scoring	(0-25)
11c.	Delay time (minutes) (99=Unknown)	(0 –85 minutes)
11d.	Cue ("boy") needed	□ o No □ 1 Yes
Sectio	n 12 — Verbal Fluency: Phonemic Test	
12a.	Number of correct F-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 12d.)	(0 -40, 95-98)
12b.	Number of F-words repeated in 1 minute	(0-15)
12c.	Number of non-F-words and rule violation errors in 1 minute	(0-15)
12d.	Number of correct L-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 13a.)	(0 -40, 95-98)
12e.	Number of L-words repeated in one minute	(0-15)
12f.	Number of non-L-words and rule violation errors in 1 minute	(0-15)
12g.	TOTAL number of correct F-words and L-words	(0-80)
12h.	TOTAL number of F-word and L-word repetition errors	(0-30)
12i.	TOTAL number of non-F/L words and rule violation errors	(0-30)

Form date: ____ / ___ / ___ __ __ __

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

Sectio	n 13 — Rey Auditory	Verbal Learning (Delayed Recall and Recognition			
13a.	Total delayed recall (If test was not completed, en TO QUESTION 14a.)	ter reason code, 95-98. If test was skipped because optional, enter 88. SKIP	(0-15, 88, 95-98)		
13b.	Intrusions		(No limit)		
13c.	Delay time (minutes) (99	=Unknown)	(0 –85 minutes)		
13d.	Recognition — Total corr	rect	(0-15)		
13e.	Recognition — Total false	e positive	(0-15)		
Sectio	n 14 — Verbal Nami	ng Test (Optional)			
14a.	Total correct without a cu (If test was not completed, en	ue ter reason code, 95-98. If test was skipped because optional, enter 88.)	(0-50, 88, 95-98)		
14b.	Total correct with phone (If test was not completed, en given, enter 88.)	mic cue ter reason code, 95-98. If test was skipped because optional or if no cues were	(0 –50, 88, 95-98)		
Sectio	n 15 — Overall appr	aisal			
15a.	15a. Per the clinician (e.g., neuropsychologist, behavioral neurologist, or other suitably qualified clinician), based on the UDS neuropsychological examination, the participant's cognitive status is deemed: 1 Better than normal for age 2 Normal for age 3 One or two test scores are abnormal 4 Three or more scores are abnormal or lower than expected 0 Clinician unable to render opinion				
Sectio	n 16 — Validity of pa	articipant's responses			
		whether hearing or other factors significantly influenced test result ta analysis to know that such an influence may have been present			
16a.	How valid do you think the participant's responses are?	1 Very valid, probably accurate indication of participant's cog 2 Questionably valid, possibly inaccurate indication of participant's cogn 3 Invalid, probably inaccurate indication of participant's cogn	pant's cognitive abilities		
16b.	What makes this participant's responses less valid?	 16b1. □1 Hearing impairment 16b2. □1 Distractions 16b3. □1 Interruptions 			
	(Check all that apply)	16b4. ☐ 1 Lack of effort or disinterest 16b5. ☐ 1 Fatigue 16b6. ☐ 1 Emotional issues 16b7. ☐ 1 Unapproved assistance 16b8. ☐ 1 Other (SPECIFY):			

Form date: ___ / ___ / ___ __ __

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org



Form D1a: Clinical Syndrome

ADRC: _	PTID: F	Form date://	Examiner's Visit #: initials:					
Langua 1 Engles 2 Sp.	glish							
	CUCTIONS: This form is to be completed by the clinician. For actim D1a. Check only one box per question.	dditional clarification and exan	nples, see the <u>UDS Coding Guidebook</u>					
1.	Diagnosis method—responses in this form are based on diagonal \square Single clinician \square Formal consensus panel \square 3	•	s or other informal group)					
Sect	Section 1 – Level of impairment – Unimpaired cognition/behavior, SCD, MCI/MBI, or dementia							
	 Does the participant have: Unimpaired cognition (e.g., cognitive performance and functional status (i.e., CDR) judged to be unimpaired)? AND Unimpaired behavior (i.e., the participant does not exhibit behavior sufficient to diagnose MBI – see MBI section starting at Q7) or dementia due to FTLD or LBD and/or FTLD behavior and language domains=0? No (SKIP TO QUESTION 3) 1 Yes (CONTINUE TO QUESTION 2a) Note: For those with longstanding cognitive impairment that does not represent a decline from their usual functioning, consider checking Question 5b for a diagnosis of "Cognitively Impaired, Not MCI/dementia". 							
Subj	ective Cognitive Decline							
2	Pa. Does the participant report 1) significant concerns aboAND 2) no neuropsychological evidence of decline AND		□ 0 No (END FORM HERE) □ 1 Yes					
2	b. As a clinician, are you confident that the subjective cogmeaningful?	nitive decline is clinically	0 No (END FORM HERE) 1 Yes (END FORM HERE)					
Dem	entia criteria							
Partic	irement #1: ipant has cognitive or behavioral (neuropsychiatric) coms that meet <u>all of the following criteria</u> :	Requirement #2: Participant must have imp following domains:	pairment in <u>one* or more</u> of the					
 Interfere with ability to function as before at work or at usual activities Represent a decline from previous levels of functioning Are not explained by delirium or major psychiatric disorder Include cognitive impairment detected and diagnosed through a combination of: 1) history-taking; 2) objective assessment (bedside or neuropsychological testing) Impaired ability to acquire and remember new information impaired reasoning and handling of complex tasks, poor judgment Impaired visuospatial abilities Impaired language functions Changes in personality, behavior, or comportment * In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, visuospatial in posterior cortical atrophy, etc.), the participant must not fulfill criteria for MCI. 								
3.	Does the participant meet criteria for dementia?		0 No (CONTINUE TO QUESTION 4) 1 Yes (SKIP TO QUESTION 6a)					

naccmail@uw.edu ALZHEIMER'S COORDINATING CENTER naccdata.org

Participan	t ID: Form date:	/ _	/		Visit #:			
Section	n 1 – Level of impairment					continued		
MCI cor	e clinical criteria							
Check all	criteria that apply in Q4.							
	 Clinical concern about decline in cognition compared to participant's prior level of lifelong or usual cognitive function (e.g., based on input from participant, co-participant, and/or the clinician's judgment, CDR SB 0.5+, etc.) Impairment in one or more cognitive domains, compared to participant's estimated prior level of lifelong or usual cognitive function, or supported by objective longitudinal neuropsychological evidence of decline Largely preserved functional independence OR functional dependence that is not related to cognitive decline (e.g., based on clinical judgment) 							
Q4 are ch	e criteria are checked, choose 1=Yes for Q4b. If les. ecked, with the exception of the third MCI criteria <mark>. !y the third MCI criteria is met in Q4, select 0=No i</mark>	ilone , conside						
4b.	Does the participant meet all three of the aboamnestic)?	ve criteria for	MCI (amnestic	or non-	0 No (CONTIN	UE TO QUESTION 5) O QUESTION 6a)		
Cogniti	vely impaired, not MCI/dementia							
impairme	ose of the "Cognitively impaired, not MCI/deme ent or decline who do not meet formal MCI crite	ria.				nce of cognitive		
	l applicable criteria for cognitively impaired,							
	1 Evidence of functional impairment (e.g., CDR 1 Cognitive testing is abnormal but no clinical 1 Longstanding cognitive difficulties, not represente TBI, other medical condition with clear effect 1 Other (SPECIFY):	concern or fu senting a dec	nctional declin	e (e.g., CD	R SB=0 and FAS= 0)		
If any of t	he criteria in Q5 are met choose 1=Yes for Q5b.							
5b.	Does the participant meet any criteria for cog	nitively impai	red, not MCI/de	ementia?	O No (SKIP TO			
Affecte	d Domains – Dementia and MCI							
neuropsy	omains that are impaired at the current visit ba chological testing. <u>Select one or more</u> as Impai	red; all others	will default to	unimpair	ed in the NACC da	atabase.		
(not in th	pehavior changes: For patients with dementia we e following MBI section) by marking Q6f as Imp ext of an MCI (or as an isolated) symptom, consid	aired and ski	pping the MBI	section (SI	(IP TO Q8). For bel			
						Impaired		
6a.	Memory					<u></u> 1		
6b.	Language					□1		
6с.	Attention					<u></u> 1		
6d.	Executive					□1 —		
6e.	Visuospatial					□1		
6f.	Behavioral (for participants with dementia only	see MBI for M	CI participants,			□ ₁		
6g.	Apraxia					□1		

Participan	t ID: Form date: / / Visit #:					
Sectio	n 1 – Level of impairment	continued				
Mild Be	havioral Impairment (MBI) core clinical criteria					
 Part pers Sym Late Not long Sym Larg mini 7. Do (Iff M (N) of 	cipant, co-participant, or clinician identifies a change in the participant's affect, motivation, thought content, bonality that is clearly different from their usual affect, motivation, thought content, behavior, or personality ptoms have been present at least intermittently for the last six months or longer onset (i.e., age > ~50, unless early onset neurodegenerative syndrome is suspected) explained by delirium, other psychiatric disorder by DSM criteria (including recent onset, longstanding or recu standing disorder). ptoms interfere with at least one of these: work, interpersonal relationships, social activities ely preserved independence in other functional abilities (no change from prior manner/level of functioning, or mal aids or assistance) Descriptions the participant meet criteria for MBI? Descriptions we provided the participant meets criteria for dementia an MBI diagnosis is excluded.) Descriptions indicated in any domain below, the participant should have a corresponding symptom checked on Form B9 — Clinic Symptoms, either from among the specific symptoms denoted there, or in "other")	rrence of r uses FION 8) QUESTION 7a) tian Judgment No Yes				
7a.						
7b. 7c.						
7c. 7d.		\square_0 \square_1				
7a. 7e.						
	on 2 – Clinical syndrome					
MCI or M cognitive Diagnose may have	The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropriate MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiological Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known and may have influenced the clinical diagnosis.					
Select the	e predominant syndrome as present; all others will default to Absent in the NACC database.	Present				
8a.	Amnestic predominant syndrome	□ ₁				
8b.	Dysexecutive predominant syndrome	□ ₁				
8c.	Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome)	□ ₁				
8d.	Primary progressive aphasia (PPA) syndrome:	□ ₁				
86	If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech 5 PPA other/not otherwise specified					
8e.	Behavioral variant frontotemporal (bvFTD) syndrome	□ ₁				
8f.	Lewy body syndrome					
8	f1. If present, select one: 1 Dementia with Lewy bodies 2 Parkinson's disease 3 Parkinson's disease dementia syndrome					
8g.	Non-amnestic multidomain syndrome, not PCA, PPA, bvFTD, or DLB syndrome	□ 1				

Sec	tion 2	2 – Clinical syndrome					continu	ıed
500		- Cilinean Syrian Sinc					Pres	
۶	8 h. Pr	imary supranuclear palsy (PSP) syndrome					ries	
	8h1. If present, select one: 1 Richardson's syndrome criteria 2 Non-Richardson's							
	8i. Traumatic encephalopathy syndrome							
	8j. Co	orticobasal syndrome (CBS)]1
8	Bk. M	ultiple system atrophy (MSA) syndrome]1
8k1. If present, select one: 1 MSA-predominant cerebellar ataxia (MSA-C) 2 MSA-predominant Parkinsonism (MSA-P) 3 MSA-predominant dysautonomia								
	81. Ot	her (SPECIFY):]1
9.		ite the source(s) of information used to assign the cli one or more as Yes ; all others will default to No in the	-					
							Ye	es
ġ	a. Cl	inical information (history, CDR)]1
٥	b. Co	ognitive testing]1
9	9c. Bi	omarkers (MRI, PET, CSF, plasma)]1
Sect	ion 3	– Primary or contributing non-neuro	degene	erative	or non-	CVD conditi	ons	
This m	nust be tion is a	of Section 3 is to identify conditions or disorders tha filled out for those with cognitive or behavioral imparts primary, contributing, or non-contributing cause of	airment (i.e the observ	., MCI, MI ved impa	31, dementia irment, bas	a, etc.) Indicate ved on the clinicia	hether a given n's best judgm	ı ent.
leave		more condition(s) as Present ; if there are no primary ditions blank. All conditions left blank will default to a y.						
		liagnose a disorder, DSM-5-TR criteria require that sational, or other important areas of functioning. For i						
		Condition	Present		Primary	Contributing	Non-contribu	uting
10.	Major	depressive disorder (DSM-5-TR criteria*)		10a.	□ 1	\square_2	\square_3	
11.	Other	specified depressive disorder (DSM-5-TR criteria*)		11a.	□ 1	\square_2	□3	
12.	Bipola	ar disorder (DSM-5-TR criteria*)	_1	12a.	1	\square_2	□ ₃	
13.	Schizo criteri	ophrenia or other psychotic disorder (DSM-5-TR a*)	□ 1	13a.	□ 1	\square_2	□3	
14. Anxiety disorder (DSM-5-TR criteria*)						3		
	If	present, (SPECIFY) (check all that apply):						
	14b.	☐ 1 Generalized anxiety disorder						
	14c.							
	14d.	\square 1 Obsessive-compulsive disorder (OCD)						
	14e.	1 Other (SPECIFY):						
15.	Post-t	raumatic stress disorder (PTSD)(DSM-5-TR criteria*)	□ 1	15a.	□ 1	□ 2	3	

Form date: ____ / ___ / ___ __ __ __

Visit #:

rarticipant iD. romi date. / / visit π.	Participant ID:	Form date:	1	Visit #:
	rarticipant ib.	ronn date.	1	VISIL #

Section 3 – Primary or contributing non-degenerative or non-CVD conditions continued.						continued
	Condition	Present		Primary	Contributing	Non-contributing
16.	Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia)	□ 1	16a.	□ 1	□ 2	□ ₃
17.	Delirium (DSM-5-TR criteria*)	□1	17a.	□ 1	\square_2	3
18.	Other psychiatric disorder (DSM-5-TR criteria*)	□ 1	18a.	□ 1	\square_2	□ 3
	18b. If present, (SPECIFY):					
19.	Traumatic brain injury (Distinct from TES and CTE, which are documented as a Clinical Syndrome and Etiologic Diagnosis, respectively)	□ 1	19a.	□ 1	□ 2	3
20.	Epilepsy	□ 1	20a.	□ 1	\square_2	3
21.	Normal-pressure hydrocephalus	□ ₁	21a.	□ 1	\square_2	3
22.	CNS Neoplasm		22a.	□ 1	\square_2	□ 3
22	b. If present, select one: 1 Benign 2 Malignant					
23.	Human immunodeficiency virus (HIV) infection		23a.	□ 1	\square_2	□ 3
24.	Post COVID-19 cognitive impairment	□ ₁	24a.	□ 1	\square_2	□ 3
25.	Sleep apnea (i.e., obstructive, central, mixed or complex sleep apnea)	□ 1	25a.	□1	2	□ 3
26.	Cognitive impairment due to other neurologic, genetic, infectious conditions (<i>not listed above</i>), or systemic disease/medical illness (as indicated on Form A5/D2)	□ 1	26a.	□ 1	□ ₂	□ 3
26	b. If present, (SPECIFY):					
27.	Cognitive impairment due to alcohol use or abuse		27a.	□ 1	\square_2	□3
28.	Cognitive impairment due to substance use or abuse	□ ₁	28a.	□ ₁	\square_2	□3
29.	Cognitive impairment due to medications	□1	29a.	□ 1	<u></u>	□ 3
30.	Cognitive impairment not otherwise specified (NOS)	□ 1	30a.	□ 1	\square_2	3
30	b. If present, (SPECIFY):					
31.	Cognitive impairment not otherwise specified (NOS)	□1	31a.	□ ₁	\square_2	3
31	b. If present, (SPECIFY):					
32.	Cognitive impairment not otherwise specified (NOS)	□ 1	32a.	□ 1	\square_2	3
32	b. If present, (SPECIFY):					



Examiner's

Form D1b: Etiological Diagnosis and Biomarker Support

Langu □1 Er □2 Sp	nglish	Form date/		Visit #: initi	dis			
	RUCTIONS : This form is to be completed by the clinician for a cation and examples, see <u>UDS Coding Guidebook for For</u>				onal			
	 Were any biomarker results used to support the current etiological diagnosis? (Consider any biomarker results from any time that may be clinically relevant) □ 0 No (SKIP TO QUESTION 12) □ 1 Yes (CONTINUE TO QUESTION 2) 							
	tion 1 – Biomarkers and imaging							
diagr sourc not in	olete this section if any of the following biomarker measunesis, including unimpaired individuals who have biomarle available and the related questions for each supporting itended to capture actual data values or register sample aused by the clinician (or at consensus) to inform an etiology.	ker characterization g data. Then comple availability; instead	i. Please complete ete Section 2: Eti	e the checklist below ological Diagnosis. T	for each data his section is			
Flui	ds							
	<u> </u>	2 Yes, only CSF-ba	based biomarker QUESTION 3, and sased biomarkers v	rs were used SKIP QUESTIONS 4 – 40 were used (SKIP TO QU biomarkers were used	JESTION 4)			
Please use the following questions to indicate the results of the fluid biomarker test(s) used by the clinican (or at consensus) to								
	e use the following questions to indicate the results of the raine the etiological diagnosis at this visit.	e fluid biomarker te	est(s) used by the	clinican (or at consen	sus) to			
deter If a flu consi		is, select 0=Not co biomarker was fou	nsistent . If a fluid nd to be indetern	biomarker was found	l to be			
If a fluctions one of	mine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent . If a fluid	is, select 0=Not co biomarker was fou	nsistent . If a fluid nd to be indetern	biomarker was found	l to be			
If a fluctions one of	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using flu ood-based biomarkers	is, select 0=Not co biomarker was fou uid biomarkers, sele No,	nsistent. If a fluid nd to be indetern ect 8. Yes,	biomarker was found ninate, select 9 . In cas	I to be es where			
If a fluctonsi one consi	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using flu ood-based biomarkers . Consistent with AD	is, select 0=Not co biomarker was fou uid biomarkers, sele No, inconsistent	nsistent. If a fluid nd to be indetern ect 8. Yes, consistent	biomarker was found ninate, select 9 . In cas Indeterminate	Not assessed			
If a fluctonsione consistence	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using flu ood-based biomarkers Consistent with AD	is, select 0=Not co ol biomarker was fou uid biomarkers, select No, inconsistent	nsistent. If a fluid nd to be indeterned 8. Yes, consistent	biomarker was found ninate, select 9 . In cas Indeterminate	Not assessed			
If a fluctonsione consistence	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnosis stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with LBD	is, select 0=Not co ol biomarker was fou uid biomarkers, select No , inconsistent	nsistent. If a fluid nd to be indeterment 8. Yes, consistent	biomarker was found ninate, select 9 . In cas Indeterminate 99	Not assessed			
deter If a fliconsi one c 3. Bl 3a. 3b. 3c. 3d.	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnosis stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with LBD	is, select 0=Not co t biomarker was fou uid biomarkers, select No , inconsistent	resistent. If a fluid not to be indeterment 8. Yes, consistent	biomarker was found ninate, select 9 . In case Indeterminate	Not assessed			
deter If a fliconsi one c 3. Bl 3a. 3b. 3c. 3d.	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnosistent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with LBD Consistent with other etiology (SPECIFY):	is, select 0=Not co t biomarker was fou uid biomarkers, select No , inconsistent	resistent. If a fluid and to be indeterment 8. Yes, consistent 1 1 1 1 1 Yes,	biomarker was found ninate, select 9 . In case Indeterminate 9 9 9 9	Not assessed 8 8 8 8 8 8 8 Not			
deter If a fliconsi one c 3. BI 3a. 3b. 3c. 3d.	rmine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnosistent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with tabb Consistent with other etiology (SPECIFY): SF-based biomarkers Consistent with AD	is, select 0=Not conbiomarker was fou uid biomarkers, select No, inconsistent	resistent. If a fluid and to be indeterment 8. Yes, consistent 1 1 1 Yes, consistent	biomarker was found ninate, select 9. In case Indeterminate 9 9 9 9 19 Indeterminate	Not assessed Not assessed 8 8 8 8 Not assessed			
deter If a fliconsi one c 3. BI 3a. 3b. 3c. 3d. 4. CS	mine the etiological diagnosis at this visit. uid biomarker was used to exclude an etiological diagnosistent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with other etiology (SPECIFY): SF-based biomarkers Consistent with AD Consistent with AD	is, select 0=Not conbiomarker was fou uid biomarkers, select No, inconsistent 0 0 0 No, inconsistent	resistent. If a fluid and to be indeterment 8. Yes, consistent 1 1 1 Yes, consistent	biomarker was found in the select 9. In case Indeterminate 9	Not assessed Not assessed R R R R R R R R R R R R R R R R R R			

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

Sec	ction	1 – Biomarkers and imaging					ontinued
lma	aging						
5. Imaging – Was imaging used for assessing etiological diagnosis? 0 No (SKIP TO QUESTION 8) 1 Yes, only PET/SPECT imaging was used (CONTINUE TO QUESTION 6, and SKIP QUESTIONS 7 – 7a3f) 2 Yes, only MR imaging was used (SKIP TO QUESTION 7) 3 Yes, both PET/SPECT and MR imaging were used							a3f)
		the following questions to indicate the results of the diagnosis at this visit.	e imaging used by t	he clini	can (or at	consensus) to determ	nine the
diag	gnosis,	was used to exclude an etiological diagnosis, select select 1=Yes, consistent . If imaging was found to be not assessed using imaging, select 8 .					
6. P	ET/SF	PECT					
6		acer-based PET - Were tracer-based PET measures u ological diagnosis?	sed in assessing an	1	Yes, resul	TO QUESTION 6b) ts were normal or abr ts were indeterminate	
	If use	d in diagnosis, indicate the results:		No	Yes	Indeterminate	Not assessed
	6a1.	Elevated Amyloid		О	□ ₁	<u> </u>	□8
	6a2.	Elevated tau pathology		О	□ 1	<u> </u>	□8
etiological diagnosis?			Yes, resul	TO QUESTION 6c) ts were normal or abr ts were indeterminate			
			No, inconsistent		es, istent	Indeterminate	Not assessed
	6b1.	Consistent with AD	□ ₀] 1	9	8
	6b2.	Consistent with FTLD	□ ₀] 1	9	8
	6b3.	Consistent with LBD	\square_0] 1	9	□8
	6b4.	Consistent with other etiology (SPECIFY):	О] 1	□ 9	□8
6		opamine Transporter (DAT) Scan - Was DAT Scan da ed to support an etiological diagnosis?	ata or information		Yes, resul	ts were normal or abr ts were indeterminate	
6	su	her tracer-based imaging - Were other tracer-base pport an etiological diagnosis? PECIFY):	d imaging used to	1	Yes, resul	TO QUESTION 7a) ts were normal or abr ts were indeterminate	
			No, inconsistent		es, istent	Indeterminate	Not assessed
	6d1.	Consistent with AD		_			
	6d2.	Consistent with FTLD	□ ₀	_	_ ·] ₁	<u>□</u> 9	□8
	6d3.	Consistent with LBD	□ ₀		_ ·] 1	9	□8
	6d4.	Consistent with other etiology (SPECIFY):	О]1	<u>9</u>	□ 8

Form date: ____ / ___ / ___ __ ___ ____

Participant ID:			Forn	n date:	/ / _	Visit #:		Visit #:	#:	
Secti	on 1 –	Biomai	rkers and imaging						continued	
7. Structural Imaging										
7a. Structural Imaging (i.e., MRI or CT) – Was structural information used to support an etiological diagram				maging data or	□ 0 No (SKIP TO QUESTION 8) □ 1 Yes, results were normal or abnormal □ 2 Yes, results were indeterminate					
				No, inconsistent	Yes, consistent		Indeterminate	Not assessed		
78	a1. At	Atrophy pattern consistent with AD		□0			9	□8		
78	a2. At	Atrophy pattern consistent with FTLD		□ ₀	□ 1		9	□ 8		
78	a3. Co	onsistent v	vith Cerebrovascular disea	ase (CVD)	□ ₀			9	□ 8	
	lf t	f there is evidence for CVD on imaging, indicate the findings:			e findings:	No	Yes	Indeterminate	Not assessed	
	7a3a.	13a. Large vessel infarct(s)					□ 1	<u></u> 9	□8	
	7a3b. Lacur		cunar infarct(s)		О	□ 1	<u></u> 9	□8		
7a3c.		Macroh	Macrohemorrhage(s)			О	□ 1	<u></u> 9	8	
7a3d.		Microhe	Microhemorrhage(s)			\square_0	□ 1	<u></u> 9	□8	
	7a3e.	3e. White matter hyperintensity				О	□ 1	<u></u> 9	□8	
7a3e1. If Yes, choose the severity: 1 Moderate white-matter hyperintensity (CHS score 5-6) 2 Extensive white-matter hyperintensity (CHS score 7-8+)										
Other biomarker modalities (e.g., tissues, skin, retinal imaging, etc.)										
Please use the following questions to indicate the results of any additional biomarker modalities used by the clinician (or at consensus) to support the etiological diagnosis at this visit.									r at	
If a biomarker modality was used to exclude an etiological diagnosis, select 0=Not consistent . If a biomarker modality was found to be consistent with a diagnosis, select 1=Yes, consistent . If a biomarker was found to be indeterminate, select 9 . In cases where one or more of the etiologies listed were not assessed using a biomarker modality, select 8 .										
 Other biomarker modality - Was another biomarker mosupport an etiological diagnosis? (SPECIFY): 				iomarker mod	dality used to	 0 No (SKIP TO QUESTION 11) 1 Yes, results were normal or abnormal 2 Yes, results were indeterminate 				
					No, inconsistent		es, istent	Indeterminate	Not assessed	
8a.	Consis	stent with	AD		□0]1	9	□ 8	
8b.	b. Consistent with FTLD			□ ₀		1	9	8		
8c.	Consistent with LBD			□ ₀]1	9	8		
8d.	8d. Consistent with other etiology (SPEC)		other etiology (SPECIFY):		О]1	<u> </u>	□8	

9. O	on 1 – Biomarkers and imaging ther biomarker modality - Was another biomarker mod pport an etiological diagnosis? PECIFY):	dality used to	o No (SKIP TO QUESTION 11) 1 Yes, results were normal or abnormal 2 Yes, results were indeterminate			
		No, inconsistent	Yes, consistent	Indeterminate	Not assessed	
9a.	Consistent with AD	□ ₀	□ 1	<u></u> 9	□8	
9b.	Consistent with FTLD	□ ₀	□ 1	<u> </u>	□8	
9c.	Consistent with LBD	О	□ 1	<u></u> 9	□8	
9d.	Consistent with other etiology (SPECIFY):	О	□ 1	<u></u> 9	□8	
 Other biomarker modality - Was another biomarker mod support an etiological diagnosis? (SPECIFY): 		dality used to	☐ o No (SKIP TO QUESTION 11) ☐ 1 Yes, results were normal or abnormal ☐ 2 Yes, results were indeterminate			
		No, inconsistent	Yes, consistent	Indeterminate	Not assessed	
10a.	Consistent with AD	□ ₀	□ 1	<u></u> 9	□8	
10b.	Consistent with FTLD	□ ₀	□ 1	9	□8	
	Consistent with LBD	□ ₀	□ 1	<u></u> 9	□8	
10c.				_		
10c. 10d.	Consistent with other etiology (SPECIFY):	□ ₀	□ 1	<u></u> 9	8	
10d.	Consistent with other etiology (SPECIFY): ortive genetics	□o	<u></u> 1	<u></u> 9	8	

Participant ID:	Form date:	/	/	Visit #:

Section 2 - Etiological diagnoses

Using all the available data (i.e. clinical, cognitive, biomarker, etc) please provide an etiological diagnosis. For those with no biomarker data, enter a **presumed** etiological diagnosis.

<u>Must be filled out for all participants</u>. Indicate whether a given condition is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician's best judgment. Select one or more etiological diagnoses from questions (*below*) as **Present**; all others will default to **Absent** in the NACC database. *Only one diagnosis should be selected as* **1** = **Primary**.

<u>For unimpaired participants:</u> Proceed using your center's diagnostic philosophy to determine whether the etiology is present and primary, contributing, or non-contributing or leave the checkboxes blank.

	Etiological Diagnoses	Present		Primary	Contributing	Non- contributing
12.	Alzheimer's disease	□ 1	12a.	□ 1	2	□ 3
13.	Lewy body disease	□ 1	13a.	□ 1	_2	□ 3
14.	Frontotemporal lobar degeneration (FTLD)	□ 1				
	If present , select all that apply:					
	14a. Progressive supranuclear palsy (PSP)	□ ₁	14a1.	□ 1	\square_2	□3
	14b. Corticobasal degeneration (CBD)	□ ₁	14b1.	□ 1	\square_2	□3
	14c. FTLD with motor neuron disease	□ 1	14c1.	□ 1	\square_2	□ 3
	14d. FTLD - not otherwise specified (NOS)	□ 1	14d1.	□ 1	\square_2	3
	14e. If FTLD (QUESTION 14) is present, specify FTLD s 1 Tauopathy 2 TDP-43 proteinopathy 3 Other (SPECIFY): 9 Unknown	,				
15.	Vascular brain injury (based on clinical and imaging evidence according to your Center's standards)	□ 1	15a.	□ 1	□2	□ 3
16.	Multiple system atrophy	□ 1	16a.	□ 1	\square_2	3
17.	Chronic traumatic encephalopathy (CTE)	□ 1	17a.	□ 1	\square_2	3
	17b. If CTE (QUESTION 17) is present, specify certaint 1 Suggestive CTE 2 Possible CTE 3 Probable CTE	y:				
18.	Down syndrome	□ 1	18a.	□ 1	_2	3
19.	Huntington's disease	□ 1	19a.	□ 1	2	3
20.	Prion disease (CJD, other)	□ 1	20a.	□ 1	2	3
21.	Cerebral amyloid angiopathy	□ 1	21a.	□ 1	2	□ 3
22.	LATE: Limbic-predominant age-related TDP-43 encephalopathy	□ ₁	22a.	□ 1	□ ₂	□ 3
23.	Other (SPECIFY):	□ 1	23a.	□ 1	\square_2	3

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org